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Abstract 
The antimicrobial activity of many of their natural products has brought prominence to the 
Streptomycetaceae, a family of Gram6positive bacteria that inhabit both soil and aquatic 
sediments. In the natural environment, antimicrobial compounds are likely to limit the 
growth of competitors, thereby offering a selective advantage to the producer, in particular 	
when nutrients become limited and the developmental programme leading to spores 

commences. The study of the control of this secondary metabolism continues to offer 
insights into its integration with a complex lifecycle that takes multiple cues from the 
environment and primary metabolism. Such information can then be harnessed to devise 
laboratory screening conditions to discover compounds with new or improved clinical 
value. Here we provide an update of the review we published in NPR in 2011. Besides 
providing the essential background, we focus on recent developments in our 
understanding of the underlying regulatory networks, ecological triggers of natural product 
biosynthesis, contributions from comparative genomics and approaches to awaken the 
biosynthesis of otherwise silent or cryptic natural products. In addition, we highlight recent 	
discoveries on the control of antibiotic production in other Actinobacteria, which have 

gained considerable attention since the start of the genomics revolution. New technologies 
that have the potential to produce a step change in our understanding of the regulation of 
secondary metabolism are also described.  
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1. INTRODUCTION 
Streptomyces species are renowned for their ability to produce a multitude of bioactive 
secondary metabolites, some of which have been co6opted clinically as a source of 
antibacterial, anticancer, antifungal, antiparasitic and immunosuppressive agents 165. The 
secondary metabolites produced by this taxon offer a chemical diversity that greatly 
exceeds that of libraries of compounds synthesized chemically and have been pre6	
selected through millions of years of evolution to interact effectively with biological targets. 

With the development of numerous approaches for counter selecting compounds with 
activities that have been previously characterised and in the case of antibiotics might have 
been rendered ineffective by the emergence of resistance, natural products are being 
revisited as a potential source of new pharmaceuticals 6, 7. 
The biological role of antibiotics has been a topic of some debate. Whilst antibiotics 
in the natural habitat are typically regarded as weapons, in the same way as they are used 
in the clinic 8610, it has been argued that at least some could function primarily in cell 
communication and signalling 11613. The latter view was based largely on the believe that 
compounds with antibiotic activity are unlikely to reach concentrations in the soil that block 	
growth, as defined by the minimal inhibitory concentration (MIC). However, selection for 

resistance occurs even at concentrations far below the MIC and antibiotic6sensitive strains 
are demonstrably disadvantaged in competing for growth, 14616. 
The majority of the antibiotics that are used in the clinic are produced by 
actinobacteria, which are high G+C, Gram6positive bacteria. Of the actinobacteria, 
perhaps the most prolific antibiotic producers are members of the genus Streptomyces, 
which belong to the family Streptomycetaceae 2, 17, 18. Streptomycetes are found in 
environments with varying nutrient supply, and metabolise a variety of carbon, nitrogen 
and phosphate sources. To respond appropriately to the challenges imposed by the 
environment, the genome of the model streptomycete S. coelicolor harbours a staggering 	
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700 regulatory genes 19. Streptomycetes have a multicellular life cycle, which culminates in 

sporulation. The reader is referred elsewhere for details of this process 20624. In brief, 
streptomycetes grow as non6motile, vegetative hyphae to produce a network of interwoven 
filaments called vegetative mycelium. When reproduction is required, for example at the 
time when nutrients run out, the vegetative mycelium acts as a substrate for newly formed 
aerial hyphae that eventually differentiate into chains of unigenomic exospores. 
Genes required for the transition from vegetative to aerial growth are typically 
referred to as bld genes, referring to their bald phenotype, due to their failure to produce 
the fluffy white aerial hyphae 25. Mutants that produce aerial hyphae but no spores are 
referred to as whi mutants, for their white phenotype caused by the lack of the grey spore 	
pigment 26. Many of the bld and whi mutants that had been isolated in the 1970s by 

phenotypic screening have later been identified by genetic complementation experiments, 
and they have been instrumental in providing better insights into the regulatory cascades 
that control morphological differentiation. For details we refer the reader to excellent 
reviews elsewhere 2, 23, 27630. 
Production of bioactive compounds is typically linked to the developmental lifecycle, 
and antibiotics are presumably produced to safeguard the nutrient supply during 
developmental growth 31633. Streptomycetes produce an arsenal of degradative enzymes 
(e.g. glycosyl hydrolases, lipases and proteases), which combined with the production of 
antibiotics and the ability to form desiccation6resistant exospores has facilitated their 	
success in a multitude of soil environments and sediments including those of marine and 

freshwater ecosystems. The competitive attributes possessed by streptomycetes have not 	
gone unutilised by higher organisms. For instance, it has become clear that many insects, 	
animals and plants engage in protective symbioses with antibiotic6producing Streptomyces 	
species (reviewed in 34, 35. However, not all interactions between streptomycetes and 	
higher organisms are beneficial 6 a minority of species produce a cellulose synthase 	
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inhibitor called thaxtomin and a coronafacic acid6like phytotoxin, which lead to the 	
development of scab diseases on potato and other tap6root crops 36, 37. 	
Over the past 50 years, S. coelicolor has been the major model for the study of 	
antibiotic production and its control. Early on it was apparent that this strain produced 		
numerous natural products, including actinorhodin (Act; 38), undecylprodigiosin (Red; 39), 	

the calcium6dependent antibiotic (Cda; 40) and plasmid6encoded methylenomycin (Mmy; 

41). The genes that encode the machinery for the production of these respective antibiotics 

are clustered together in ‘biosynthetic gene clusters’ (BGCs), which typically also harbour 

resistance gene(s) and one or more transcriptional regulators that control biosynthesis. 

Sequencing of the S. coelicolor genome was a landmark event that revealed an 

unexpected potential for the production of hitherto unidentified or cryptic natural products 

19, with more than 20 BGCs specifying a diverse range of secondary metabolites 42, 43. One 

of these is a so6called cryptic polyketide antibiotic (later named coelimycin), which is only 

produced under specific growth conditions 44, 45. Sequencing of other model actinobacteria 
	
revealed a similar picture, with some species harbouring more than 50 different BCGs 466


51. Thus, the potential of actinobacteria as producers of bioactive molecules was found to 
be much greater than was initially thought. This prompted the sequencing and analysis of 
the genomes of a large array of species to identify novel BGCs (reviewed in 52655) plus the 
development of approaches to induce the production of natural products under laboratory 
conditions 1, 56659. The identification of BGCs is now relatively routine using bioinformatics 
tools, such as antiSMASH 60, CLUSEAN 61 and PRISM62 . Available also are tools for the 
identification of BGCs corresponding to specific classes of natural product, e.g. 
NRPSPredictor for nonribosomal peptides 63, BAGEL for bacteriocins and lantibiotics 64 
and SEARCHPKS for polyketides 65. For a comprehensive overview of the available 	
bioinformatic tools for genome mining we refer the reader to excellent reviews elsewhere 

66, 67. 
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This review is intended to be an update to our comprehensive review on the same 
subject published in this journal in 2011 33. The broad subject is covered, but in the interest 
of limiting duplicated content, the reader is often referred to our previous review. Here, the 
focus lies on recent insights into the regulation of natural product biosynthesis in 
streptomycetes, based on the literature from the period of 201162017. The article focuses 
on both pleotropic and cluster6situated regulators, highlighting recent discoveries. We 
thereby give specific attention to the control of antibiotic production in other actinobacteria. 
We also provide an update on our understanding of the links between primary and 	
secondary metabolism and ecological triggers that stimulate natural product biosynthesis, 

and outline methodology that could be used to activate silent or cryptic natural product 
biosynthetic pathways. 
 
2. TRANSCRIPTIONAL REGULATION BY CLUSTERSITUATED REGULATORS 
Over the last several decades, investigations into the regulation of the antibiotics produced 
by S. coelicolor (Act, Red, Cda, Mmy and coelimycin) and that of streptomycin 
biosynthesis by S. griseus have established key aspects of the regulation of secondary 
metabolism in Streptomyces. For details we refer to reviews elsewhere 31633. The 
regulation of secondary metabolism is complex and frequently involves pleotropic global 	
regulators that either directly activate or repress biosynthetic genes or do so via cluster6

situated repressors or activators. A plethora of regulatory proteins is involved in the control 
of antibiotic production, across a broad range of regulator families. and cross6regulation 
results in a highly complex regulatory network. This is necessary to correctly interpret the 
environmental signals and translate them into appropriate transcriptional responses, so as 
to time the production of natural products, often closely connect to development. The 
different families of transcriptional regulators known to be involved in the control of 
antibiotic production, and some well6studied examples, are provided in Table 1. 
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The regulation of the BGCs for actinorhodin (Act; controlled by ActII6ORF4), 
undecylprodigiosin (Red, controlled by RedD) and calcium6dependent antibiotic (Cda, 	
controlled by CdaR) of S. coelicolor and for streptomycin (Str, controlled by StrR) are the 

most well6studied examples of cluster6situated regulators (CSRs). ActII6ORF4, CdaR and 
RedD belong to the SARP family of Streptomyces antibiotic regulatory proteins 68, while 
StrR unusually belongs to the family of ParB6Spo0J proteins, most of which are involved in 
DNA segregation and sporulation 69. All available evidence supports the conclusion that 
the cellular level of a cluster6situated regulator dictates the level of transcription of its 
cognate BGC, which correlates closely with the level of production of the corresponding 
natural product 70, 71. Indeed, the timing of Red production fully depends on the promoter 
that drives the transcription of redD, allowing its use as a transcriptional reporter system 72. 
Thus, the ultimate factor deciding whether or not a BGC is expressed is its CSR(s). While 	
ActII6ORF4 and StrR act as single CSRs within their respective BCGs, production of RedD 

is in turn controlled by RedZ 73, 74, which is related to the response regulators (RR) of 
prokaryotic two6component systems (TCS) but ‘orphaned’, i.e. not genetically linked to a 
histidine kinase 75. It is becoming increasingly clear that the presence of multiple CSRs is 
more often the rule than the exception with each regulator effecting control of a subsets of 
genes or contributing to a hierarchical cascade. The latter is exemplified by the BGCs 
specifying polyene antifungal compounds such as amphotericin, nystatin, natamycin 
(pimaricin) and candicidin 76679. It has been assumed and, in some cases, shown that 
many regulators are responsive to small molecule signals. It has been assumed and in 
some cases shown that many regulators are responsive to small molecule signals. 	
Regulators responsive to autoregulatory molecules such as ɣ6butyrolactones are well 

known 80, 81, and feedback control by biosynthetic intermediates over production or export 
has been demonstrated for jadomycin, Act and simocyclinone biosynthesis 82684. However, 
the identity of the ligands/signals perceived by both pleotropic and CSRs is a major 
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question within the field, and if answered could lead to a revolution in chemical genetic 
tools for the stimulation of natural product biosynthesis, and thus drug discovery.  
 
2.1. Pathwayspecific regulation: streptomycin and actinorhodin as paradigms 
The first complete regulatory pathway leading to activation of a BCG was described for Str 
in S. griseus 85. Transcription of StrR, which as mentioned above is the corresponding 	
CSR, is activated by the pleiotropic regulator AdpA (A6factor6dependent protein; 86, whose 

transcription depends on the accumulation of the γ6butyrolactone 26isocapryloyl63R6
hydroxymethyl6γ6butyrolactone, better known as A6factor. The hormone6like compound 
binds to ArpA 87, which acts as a repressor of adpA transcription 88. AdpA also activates 
morphological differentiation, and thus plays a key role in the coordination of chemical and 
morphological differentiation 89, 90. A6factor is synthesized by the enzyme AfsA 91. The role 
of A6factor in the control of antibiotic biosynthesis is further discussed in Section 9. 
The transcription of strR is subject to multi6level control, and in particular by the 
pleiotropic regulator AtrA 92, 93, which has an orthologue in S. coelicolor that activates 
transcription of actII6ORF4, the CSR within the act cluster 94. Binding of AtrA in vivo within 	
the vicinity of the actII6ORF4 promoter has recently been confirmed by chromatin 

immunoprecipitation in combination with DNA sequencing (ChIP6seq) (McDowall et al, 	
unpubl. data). Compared to what is known about strR, the control of actII6ORF4 is 	
complex with many transcription factors reported to control its expression directly. 	
Numerous direct and indirect regulators have been identified 32, 33. Some of the most 	
recent examples are summarized in Table 2. For some of these transcription factors, 	
binding has been demonstrated in vivo by ChIP6based approaches. In addition to AtrA, 	
these include DasR 95, a member of the GntR family that controls the uptake and 	
metabolism of N6acetylglucosamine (GlcNAc) and the degradation of chitin to GlcNAc 96, 	
97, AbsA2 98, the response regulator of the AbsA TCS, which negatively controls antibiotic 		
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production in S. coelicolor 99, 100, AbrC3 101, a response regulator of a TCS that is atypical 	

in having two histidine kinases 102, and Crp 103, the cyclic AMP receptor protein, which is 

perhaps best known for mediating carbon catabolite repression of the lac operon in E. coli 

104, controls diverse cellular processes in many bacteria 105, and is a key regulator of 

secondary metabolism as well as spore germination and colony development in S. 

coelicolor 106. In addition to direct regulation, the expression of actII6ORF4 is dependent on 

relA 107, which is required for induction of the stringent response. The stringent response 

enables bacteria to survive sustained periods of nutrient deprivation by enhancing the 

transcription of numerous genes required to survive stress, while lessening transcription of 

genes, such as those specifying stable RNAs, whose products are required in significantly 
	
reduced amounts during periods of slowed growth 108, 109. Whilst the signals transduced by 


Crp and the stringent response are well described, the signals sensed or transduced by 
most of the transcription factors that bind the actII6ORF4 promoter remain to be 
elucidated. An exception is DasR, which is a receptor for glucosamine666phosphate (GlcN6
6P), an intermediate in GlcNAc metabolism, and derivatives 97. The binding of GlcN66P by 
DasR reduces its affinity for DNA, which de6represses the expression of genes that 
facilitate the degradation of chitin to GlcNAc and its uptake and metabolism 96, 97. Links 
between DasR and AtrA are described later in this review (Section 5.3). 
In addition to AraC and AbsA, several other TCSs regulate secondary metabolism 
in S. coelicolor and other actinobacteria 1106113. TCSs are the major signal6transduction 	
systems of bacteria and enable them to monitor and adapt to environmental changes 114, 

115. Streptomycetes harbour a large number of TCSs, which likely reflects the changing 
and variable nature of their natural habitats 19, 110, 116. The PhoRP TCS system is 
ubiquitous in bacteria and senses phosphate and regulates its assimilation. PhoRP plays a 
major role in the control of antibiotic production in streptomycetes 1176119. Similar has been 
found for the AfsQ1/2 TCS, which controls the biosynthesis of Act, Red and Cda in 
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response to nitrogen limitation 111 via what appears to be direct interaction with the 
promoter regions of actII6ORF4, redZ (which activates redD) and cdaR, respectively. The 
AfsQ1/2 TCS is closely related to CseBC, which responds to cell6envelope stress 75. 
Recently, it was shown that the DraRK TCS, which responds to high concentrations of 	
nitrogen 113, and the OsdRK TCS, which is oxygen6responsive, are similar in function to 

the system controlling dormancy in mycobacteria 112, 120, and are both required for Act 
production. Interestingly, in the absence of a functional DraRK system the production of 
Cpk and Red increases 113. The AbsA system has been exploited to improve the chance of 
success during screening of streptomycetes for new antibiotics by overexpression of the 
S. coelicolor homologue in other streptomycetes; this led among others to the induction of 
pulvomycin production in S. flavopersicus . Cross6talk between the different regulatory 
networks is discussed in Sections 5 and 6. 
 
2.2. Crossregulation of disparate BGCs by clustersituated regulators 	
It is well established that a CSR usually binds to promoter sequence(s) and either 

activates or represses genes only within its cognate BGC. For examples see Tables 1 and 
2. However, this is not strictly true for all CSRs. Recently, the PAS6LuxR family cluster6
situated regulator within the candicidin BGC was shown to not only activate 16 out of the 
21 genes in the gene cluster, but also to be required for expression of the antimycin BGC 
79, 121. Thus, antimycin and candicidin biosynthesis are co6ordinately controlled by FscRI in 
S. albus 121. A similar observation was made in S. avermitilis, where PteF, a member of 
PAS6LuxR family and cluster6situated activator of the filipin BGC, was proposed to cross6
regulate the production of oligomycin 122. Thus, evidence is accumulating, at least for PAS6
LuxR family regulators, that they may not in fact simply be CSRs but act more broadly to 	
co6ordinately control the biosynthesis of multiple compounds. This is likely rooted in the 

flexible inverted repeat the family of regulators appears to bind to both in vitro and in vivo 
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121, 123. It is an obvious and attractive hypothesis that production of secondary metabolites 
with antimicrobial properties or subsets thereof should be coordinated, so as to maximise 
any synergistic activity and minimise the development of resistance to the agents 
produced.  
 
3. THE IMPACT OF PHOSPHATE AVAILABILITY ON SECONDARY METABOLISM 
The impact of phosphate availability on bacterial physiology and gene expression in 
particular has been intensely studied in Streptomyces species and other bacteria 1246127. 	
Expression of a suite of genes involved in phosphate management termed the pho regulon 

is controlled by the PhoRP TCS 116, 128, 129. During phosphate starvation, the membrane6
bound sensor kinase, PhoR, undergoes autophosphorylation and transfers its phosphate 
group to the response regulator, PhoP 119, 130 (Fig. 1). The phosphorylated form of PhoP 
(PhoP6P) binds to a well conserved DNA motif called a PHO box and can either activate or 
repress expression of genes within the pho regulon 118. During growth in phosphate 
replete conditions, PhoR is prevented from phosphorylating PhoP via physical interaction 
with the phosphate6specific transport (Pst) system, a high6affinity phosphate transport 
system whose production is activated by PhoR 118, 131, 132. This interaction creates a 
regulatory loop in which the Pst system is produced at a low level during conditions of 	
phosphate sufficiency. When phosphate levels drop, PhoR is released and phosphorylates 

PhoP, which then activates transcription of genes within the Pst system and the other 
genes within the pho regulon 118. The precise signal that frees PhoR to phosphorylate 
PhoP is unknown, but it is known that the switch is reversible. 
It has been known for some 15 years that deletion of phoP can lead to earlier and 
increased production of antibiotics 119. This phenomenon was covered in our previous 
review 33 and for S. coelicolor was rooted in destabilization of a negative regulatory loop 
involving the AfsKRS system 133, 134. AfsR is a transcription factor related to SARPs that 
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when phosphorylated by AfsK activates transcription of the gene encoding AfsS, a small 
sigma factor6like protein required for antibiotic biosynthesis in S. coelicolor 1356138. In the 	
proposed regulatory loop, PhoP represses the production of AfsS and AfsR represses the 

production of PhoRP and the Pts system 135. However, recently PhoP was shown to in fact 
be an activator of afsS transcription in experiments using a full panel of phoP, afsR and 
afsR/phoP mutants and a suite of synthetic promoters engineered to prevent AfsR binding 
but not PhoP binding 139. In a revised model, PhoP hinders higher activation of afsS 
transcription by AfsR by outcompeting AfsR for binding to the afsS promoter (Fig. 1) 135, 
139. 
A series of ChIP6Chip experiments were conducted with S. coelicolor, which 
provided genome6wide insight into the role of PhoPR in controlling secondary metabolism 
140. These revealed that PhoP serves as a master regulator of secondary metabolism 	
during phosphate starvation, whereby it transiently represses pleotropic activators of 

antibiotic production and regulators of morphological development, namely bldA, which 	
specifies the leucine tRNA corresponding to the rare UUA codon, and scbAR, which 	
encodes the ɣ6butyrolactone regulatory system of S. coelicolor that positively influence 	
morphological development, and Act and Red biosynthesis 141, 142. Interestingly, the 	
ScbAR system also indirectly controls the gene expression of scbR2 whose gene product 	
activates afsK expression 143, which is the cognate sensor kinase responsible for 	
activating the global regulator of secondary metabolism, AfsR (mentioned above). Thus, 	
although PhoP activates expression of afsS, it also indirectly represses transcription of 	
afsK, which means AfsR remains unphosphorylated and inactive (Fig. 1). 		
Although there are only a handful of example thus far, it is clear that in addition to 	

controlling pleotropic regulators, PhoP can also act directly upon BGCs. For example, in S. 

coelicolor, PhoP negatively regulates the biosynthesis of Cda by repressing the cdaR 

gene 140. Interestingly, the inverse seems to be the case for the BGC specifying coelimycin 

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where there are three PHO boxes within the DNA sequence of two structural genes and 

expression of the gene cluster appears to be PhoP6dependent 140. Direct regulation of 

biosynthetic pathways by PhoP is not a peculiarity of S. coelicolor, as PhoP was recently 

shown to negatively regulate avermectin biosynthesis by repressing the expression of 

aveR, which encodes a cluster6situated activator 143. 

 
	
4. REGULATION OF SECONDARY METABOLISM BY NITROGEN 


The uptake and incorporation of nitrogen is essential for anabolism of amino acids, nucleic 
acids and peptidoglycan, among other important macromolecules. S. coelicolor can utilise 
diverse nitrogen sources including ammonia, nitrate, nitrite, urea, amino sugars and amino 
acids 1446146. Assimilation of nitrogen results in the production of glutamate and glutamine, 
which act as the primary nitrogen donors within the cell 147. Like other bacteria, 
Streptomyces species possess a sophisticated regulatory system that enables adaptation 
to nitrogen availability. Many studies have indicated that the source of nitrogen can 
influence the production of secondary metabolites. The production of most of the 
secondary metabolites is reduced by nitrogen sources that are favourable for growth 148, 	
149. This is presumably because utilization of a high6quality nitrogen source (e.g. 

ammonium) causes more of the available carbon to be consumed for growth and 
generation of biomass and thus ultimately less carbon is available for secondary 
metabolism when starvation occurs. Although the above has been known for a long time, 
the underpinning molecular detail has taken longer to elucidate. The global regulator 
controlling nitrogen metabolism is GlnR, which is an orphan response regulator without a 
cognate sensor kinase (Fig. 1) 145, 150. Deletion of glnR in S. coelicolor blocks production of 
Act and Red 151. GlnR6mediated regulation of Act and Red production was assumed to be 
indirect until a recent study demonstrated otherwise. In vitro DNA binding and DNaseI 
footprinting studies showed that GlnR binds the promoter sequence of CSRs within these 	
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BGCs (actII$ORF4 and redZ, respectively), implying that GlnR regulation is direct 152. In 

the same study, direct regulation of CSRs of avermectin and oligomycin biosynthesis 
(aveR and olmRI/RII, respectively) by GlnR in S. avermitilis was also demonstrated; thus, 
direct regulation of a subset of natural product BGCs by GlnR is likely to be universal 152. 
Several studies have recently been conducted that have enhanced the understanding of 
nitrogen metabolism and its interconnectedness with phosphate and carbon utilization. 
These connections and their implications for secondary metabolism are further discussed 
in Section 6. 
 
5. CONTROL OF ANTIBIOTIC PRODUCTION BY THE CARBON SOURCE 	
5.1. Carbon catabolite repression and the control of antibiotic production 

In the natural environment, the availability of high6energy carbon sources, for instance, 
glucose, promotes vegetative growth and suppresses morphological and chemical 
differentiation 153, 154. Examples of antibiotics whose production is repressed by glucose 
include Act in S. coelicolor 155, 156, chloramphenicol in S. venezuelae 157, Str in S. griseus 
158, and erythromycin in Saccharopolyspora erythraea 159, 160. Like in most bacteria, carbon 
utilization by streptomycetes is controlled by carbon catabolite repression (CCR), which 
ensures that high6energy carbon sources such as glucose, fructose or TCA cycle 
intermediates are utilized preferentially over energetically less favourable ones, such as 
lactose, glycerol or mannitol. The best studied system is CCR by glucose, which is often 	
referred to as glucose repression 1616164. 

In most bacteria, glucose is transported through the phosphoenolpyruvate6
dependent phosphotransferase system or PTS. The PTS encompasses Enzyme I (EI) and 
phosphocarrier protein HPr in combination with carbohydrate6specific transport complexes 
called Enzyme II (EII), which confer substrate specificity 165, 166. As a result, the PTS 
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typically plays a key role in glucose repression 104, 167, 168. However, in Streptomyces 
species, deletion of either of the genes ptsH, ptsI or crr for HPr, EI and EIIA, respectively, 
has no influence on CCR, but instead leads to a block in morphological differentiation, with 
mutants failing to produce aerial hyphae and/or spores on a reference medium such as 
R2YE agar 97, 169. This sporulation defect is surprising and may be associated with lack of 	
iron and/or copper in this medium, accompanied by a reduced production of the 

siderophore, desferrioxamine 1706172. This link between carbon availability, iron 
homeostasis and morphological differentiation has not yet been resolved. The limited role 
of the PTS in CCR may be explained by the fact that in streptomycetes, glucose is 
internalized via the GlcP permease, which belongs to the major facilitator subfamily of 
transporters 1736175. For a summary of central carbon metabolism and CCR, see Fig. 2. 
It was recognized many decades ago that randomly generated mutants lacking 
CCR are invariably mutated in the gene glkA, which encodes a glucose kinase 176, 177. 
Indeed, a targeted deletion of glkA in a clean genetic background was pleiotropically 
defective for CCR 1786180. The activity of Glk is mediated by as of yet unknown mechanism 	
181. Its role in catabolite repression may be co6ordinately controlled with a number of other 

proteins. These include SCO2127, a protein of unknown function, which is encoded by the 
gene upstream of glkA 182, 183 and regulatory proteins that control the transcriptional 
network of genes that mediate CCR, such as the global regulators Rok7B7 and DasR (see 
below). Another interesting protein is the phosphoinositide phosphatase, SblA 184. Deletion 
of sblA in Streptomyces lividans leads to relief of CCR, with accelerated growth and 
development in the presence of glucose on some media 185. These phenotypes correlated 
with reduced glucose uptake by the mutant and may therefore affect the activity of GlcP. 
The cleavage of phosphoinositides by SblA is apparently required to resume growth in 
transition phase, although the mechanism has not been elucidated 185. 	
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Studies with S. peucetius suggested the existence of an integral regulatory system 

that responds to glucose transport and metabolism, which probably elicits CCR 154. 
Indeed, addition to growth media of either of the glycolytic intermediates fructose 1,66
biphosphate and phosphoenolpyruvate results in glucose repression of daunorubicin and 
doxorubicin biosynthesis in S. peucetius 186. This connects to observations that the activity 
of GlkA depends on interaction with the glucose permease GlcP in S. coelicolor 181. 
Many antibiotics show growth phase6dependent control. As a consequence, 
developmental mutants that are blocked in an early phase of the life cycle 6 in particular 
bld mutants 6 typically fail to produce antibiotics. A well6studied case is represented by 
mutants that lack the developmental gene, bldB, as these are not only disturbed in 	
development and antibiotic production, but are also defective in CCR 187, 188. This links the 

pathways that regulate carbon utilization and morphological differentiation. BldB is a 	
member of a family of DNA6binding proteins that are only found in Actinobacteria. The 	
family is widespread in streptomycetes, with several paralogues in S. coelicolor, including 	
AbaA and WhiJ, which play a role in the control of antibiotic synthesis and development, 	
respectively 189. Identification of the BldB regulon and the way its activity is modulated will 	
likely offer important new insights into the growth phase6dependent control of antibiotic 	
production and the role of CCR in this process. 	
 	
5.2. New insights into the nutrientsensory DasR system 		
In streptomycetes, the PTS plays a major role as the first step in a global antibiotic 	

sensory system revolving around the nutrient sensory protein, DasR, which is conserved 

in streptomycetes and many other actinobacteria. DasR is a GntR6family repressor with a 

pleiotropic role in the regulation of primary and secondary metabolism and of 

development. For details, we refer to reviews elsewhere 33, 190. Here we summarise the 

key elements of the regulon and highlight recent insights (Fig. 3). The core regulon of 

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DasR in all Gram6positive bacteria revolves around the genes for aminosugar transport 

(pts) and metabolism (nag) and in streptomycetes also the genes for the chitinolytic 

system (chi). Originally identified as the repressor of the chitobiose transporter DasABC 

191, 192, it was soon recognized that DasR also controls many genes involved in antibiotic 
	
production. Comprehensive analysis of the DasR regulon of S. coelicolor showed that it 


acts as a direct and very global transcriptional repressor of antibiotic production by binding 
to the promoter regions of the CSRs for all known chromosomally located antibiotic BCGs 
in S. coelicolor 95, 97, 193, 194. DasR also represses siderophore biosynthesis via control of 
the iron6homeostasis regulator dmdR1 170, 195. A similar pleiotropic role of DasR has also 
been reported in the erythromycin producer S. erythraea 196, 197, but is not typical of all 
streptomycetes. 
The DNA6binding activity of DasR is modulated by ligands derived from GlcNAc or 
glucosamine (GlcN), in particular GlcNAc66P and GlcN66P, and the crystal structure of 
DasR and its orthologue NagR of Bacillus subtilis in complex with these ligands have been 	
elucidated 198, 199. GlcN66P stands at the cross6roads of carbon and nitrogen metabolism 

and cell6wall synthesis, and by acting as an effector of the DasR6dependent antibiotic 
control system, it plays a major role in the connection between primary and secondary 
metabolism (Fig. 3). The DNA6binding activity of DasR depends on environmental 
conditions. High concentrations of GlcNAc under famine conditions (e.g. on minimal 
media) result in inactivation of DasR, and thus derepression of its targets, leading to 
enhanced antibiotic production and development. Conversely, on rich media, GlcNAc 
represses antibiotic and development, leading to a complete developmental block 97, 194, 
200. This phenomenon is known as feast or famine; under conditions of nutritional richness, 
aminosugars are perceived as derived from chitin, signalling plenty of nutrients, while 	
under poor growth conditions (famine) it is perceived as coming from autolytic degradation 

of the cell wall and hence cell death. The latter elicits development and antibiotic 
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production. Besides the phosphorylated aminosugars GlcN66P and GlcNAc66P, other 
metabolites may also modulate the DNA6binding activity of DasR. These include high 
concentrations of phosphate (organic or inorganic), which were shown to enhance the 
binding of DasR to its recognition sites 95, 201. Thus, the affinity of DasR for its recognition 
sites (and with that the expression of its regulon, including many BGCs for natural 
products) depends on the metabolic status of the cell. Interestingly, high concentrations of 
phosphate (either organic or inorganic) enhance binding of DasR to its recognition site in 
vitro, which reinforces the PhoP6mediated repression of antibiotic production by phosphate 	
95, 201. 

Full genome6scale identification of the DasR binding sites in vivo using ChIP6chip 
analysis corroborated the identity of canonical DasR binding sites or dre (DasR6responsive 
elements), but also revealed so6called class II sites, which do not conform to the known 
consensus sequence 95. These sites are not found by the regulon prediction algorithm 
PREDetector 202. Binding of DasR to class II sites may require a co6repressor, which has 
not yet been identified. The ChIP6Chip analysis also showed that the binding profile of 
DasR changes dramatically over time, with only small overlap in the binding profiles 
between 24 (vegetative growth) and 54 hours (morphological differentiation and antibiotic 
production). Thus, the DasR regulon is a highly complex system, which is influenced by 	
metabolic status and most likely also by other regulatory proteins. Taken together, the 

metabolic status of the cell determines the selectivity of DasR for its recognition sites and 
thus the expression of its regulon, which includes many secondary metabolite BGCs. 
 
5.3. Competition between AtrA, Rok7B7 and DasR and connections to CCR 
Until the discovery of DasR, it was unclear how global carbon control was related to the 
control of specific carbon utilization regulons and antibiotic biosynthetic genes. Deletion of 
the genes for either GylR or MalR relieves both CCR and substrate induction of glycerol 
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and maltose utilization, respectively, and hence gives constitutive expression even in the 
absence of inducer, while over6expression results in hyperrepression 203, 204. This suggests 	
that a global regulatory system for carbon utilization does not exist in S. coelicolor. In most 

bacteria, global carbon control depends on the cAMP receptor protein (CRP). 
Streptomycetes do have a cAMP receptor protein, but in contrast to other bacteria, it does 
not seem to play a role in CCR. Instead, CRP plays a role in the control of germination, 
and crp null mutants show prolongued dormancy 106. Importantly, genome6wide DNA 
binding studies and transcriptional analysis revealed that CRP also globally controls 
antibiotic BGCs in S. coelicolor (103; see also section 6). 
There is also growing evidence that besides DasR, the TetR6family regulator AtrA 
plays a role in carbon utilization (Fig. 4). Very recent ChIP6seq experiments (McDowall et 
al., unpubl. data) have confirmed that AtrA binds upstream of nagE2, which encodes a 	
known permease for the uptake of GlcNAc 205. Similar to what was found for actII6ORF4, 

this binding appears to activate transcription as disruption of atrA results in reduced levels 
of nagE2 transcript (Nothaft et al, 2010). This led to the suggestion that AtrA may increase 
Act production indirectly through enhanced GlcNAc6induced inactivation of DasR as well 
as directly through activation of actII6ORF4 transcription (Nothaft et al., 2010). The control 
of DasR activity by AtrA via cellular levels of GlcNAc may extend beyond nagE2 as recent 
ChIP6seq also identified AtrA binding to recognisable motifs upstream of SCO0481, which 
encodes a protein that binds chitin (a rich source of GlcNAc), and crr (SCO1390), for the 
global PTS component EIIA, that is required for GlcNAc transport. The role of AtrA in 
carbon utilisation almost certainly extends beyond GlcNAc metabolism (Fig. 4). ChIP6seq 	
also identified AtrA binding to sites upstream of gylR (SCO1658) and glpk2 (SCO0509), 

which encodes a glycerol kinase outside the gyl operon. Control of morphological 
differentiation by AtrA is explained at least in part by transcriptional control of ssgR (Fig. 4) 
206, the transcriptional activator of the gene encoding SsgA, which is involved in cell 
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division and sporulation 207, 208. Disruption of atrA suggests it activates transcription of 
ssgR 206, and direct binding of AtrA within the upstream regulatory region of ssgR was 
confirmed by ChIP6seq (McDowall et al, unpubl. data). 
The ROK6family protein, Rok7B7 takes up an interesting position in the regulatory 
network as it connects the control of antibiotic production and carbon catabolite repression 
209. Mutants lacking rok7B7 are delayed in their developmental programme and are 	
pleiotropically disturbed in terms of antibiotic production, perhaps as a consequence of a 

yet unexplained change in CCR. Rok7B7 activates the transcription of actII6ORF4 (and 	
hence Act production) and represses the biosynthesis of Red and Cda, although its 	
binding site has so far not been identified 209, 210. Aside from actII6ORF4, Rok7B7 also 	
activates the GlcNAc pts gene, nagE2, which means it counteracts the activity of DasR in 	
a manner very similar to AtrA. 	
The signals that are required for activation of AtrA and Rok7B7 are unknown. Since 	
AtrA is a TetR6regulator it is suggested that this protein is regulated in an allosteric manner 	
by a ligand to exert its effect on secondary metabolism. In S. globisporus, AtrA is inhibited 	
by the binding of heptaene, a biosynthetic intermediate of lidamycin whose biosynthesis is 		
controlled by AtrA via activation of its CSR 211. As part of this work, it was also reported 	

that the DNA6binding activity of S. coelicolor AtrA is regulated by Act 211. Whilst this finding 

was shown with different preparations of Act, the specificity of this effect needs to be 

evaluated further. To our knowledge, in all streptomycetes atrA is co6located with a 

divergent AtrA6target gene (SCO4119 in S. coelicolor) that encodes NADH 

dehydrogenase 212. There is interest in identifying the substrate of SCO4119 as at least 

some members of the TetR family interact with ligands that are structurally identical or 

related to the substrates of proteins encoded by genes divergent to their own 213. As ChIP6

chip experiments failed to show binding of ROK7B7 to genomic DNA under standard 

growth conditions on minimal media, it was proposed that the regulator requires a co6
	
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factor or ligand to facilitate its DNA binding activity. The control of 6 and gene synteny with 


6 the xylose transport operon xylEFG by Rok7B7 hints at C56sugars as candidate ligands 
for this regulator209. 
Interestingly, there is an intricate link between Rok7B7, DasR and CCR, which in 
turn has important implications for the control of antibiotic production. Proteomic 
comparison of S. coelicolor and a glkA null mutant showed that glucose activates the 
expression of Rok7B7 in a Glk6independent manner 214, which was later confirmed by 
transcriptomic analysis 215. In turn, DasR and Rok7B7 repress the expression of glkA and 
thus CCR 95, 209, while conversely, Glk represses Rok7B7 214. Deletion of rok7B7 results in 
a loss of CCR, which directly implicates Rok7B7 in CCR 214, 215. It is unlikely however that 	
glkA is a member of the rok7B7 regulon, as glkA transcription is constitutive, and its 

activity is post6translationally controlled 181, 215. 
 In summary for this chapter, there are multiple regulatory networks that 
connect carbon control to the control of antibiotic production. Understanding carbon 
source6dependent control of antibiotic production is important from the perspective of both 
the design of growth media for yield optimization and for screening of new bioactive 
molecules. Despite the wealth of literature, it is still unclear how Glk exerts CCR, and we 
expect that more regulatory proteins that play a role in this important process will be 
discovered. It is becoming clear that there is a strong connection to the regulons of DasR, 
Rok7B7 and AtrA. Future research will need to elucidate precisely how this multi6layer 	
control network is governed. Finding the ligands for AtrA and Rok7B7 would be one of the 

major steps to take. 
 
6. CONNECTIONS BETWEEN PHOSPHATE, NITROGEN AND CARBON 
METABOLISM 
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Carbon, nitrogen and phosphate are essential components for the basic building blocks of 
all cellular life. It is reasonable to assume that acquisition and utilization of these elements 
would be coordinately controlled. Although widely accepted, molecular characterization of 
this interconnectivity has only emerged recently, with the important discovery that GlnR, 
DasR and CRP jointly regulate three genes for citrate synthesis in the erythromycin 	
producer S. erythraea 216. CRP controls early processes during growth in Streptomyces 

species 106, 217 and acts as a global regulator of Act, Cda and Red production, perhaps by 
coordinating precursor flux 103. Indeed, 8 out of 22 secondary metabolic clusters on within 
the S. coelicolor genome harbour Crp binding sites, suggesting a pleiotropic role in control 
of antibiotic production. Further evidence for the connection between C6 and N6metabolism 
via GlnR came from elegant experiments showing that several ABC transporter systems 
are under direct control of GlnR in S. erythraea, affecting growth on maltose, mannitol, 
mannose, sorbitol and trehalose 218. Recent data show that in S. coelicolor, GlnR is 
activated by glucose 215, while GlnR directly activates transcription of a putative 
carbohydrate transport operon agl3EFG 219. Taken together, these data suggest direct 	
linkage between carbon and nitrogen metabolism, albeit perhaps only when certain carbon 

sources are available. 
The understanding of links between nitrogen and phosphate metabolism in S. 
coelicolor is better developed. PhoP and GlnR control antibiotic production in response to 
the availability of phosphate and nitrogen sources, respectively 135, 220. Similar to the 
competitive activation of afsS by AfsR and PhoP described in section 3, these two 
regulators bind to overlapping regions within the glnR promoter, but unlike the afsS story, 
PhoP represses glnR transcription while only AfsR promotes it 139 (Fig. 1). When 
phosphate is plentiful, PhoP is inactive and thus AfsR (dependent on the growth phase) 
activates transcription of glnR, but when phosphate is in short supply, PhoP is 	
phosphorylated by PhoR and represses the expression of glnR (Fig. 1) 220. In addition, 

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PhoP also directly represses transcription of genes within the GlnR regulon, namely two 
glutamine synthetases (glnA and glnII) and the promoter for the amtB6glnK$glnD operon, 
which encodes an ammonium transporter and putative nitrogen sensing/regulatory 
proteins 221. Uptake/utilization of nitrogen is presumably superfluous if insufficient 
phosphate is available, hence the PhoP6mediated repression of genes involved in these 
processes. Thus, PhoP6mediated control of nitrogen metabolism may help balancing the 
cellular P/N equilibrium.  
Connection between phosphate and carbon metabolism is less well studied, but 
one link may be governed via the PhoP6controlled enzyme PPK (polyphosphate kinase), 	
which affects antibiotic production in response to the level of inorganic phosphate (Pi) 127, 

222. PPK is involved in maintaining the cellular energy balance by regenerating ATP from 
ADP and polyphosphates and ppk mutants show enhanced Act production under Pi6
limited growth conditions 127. This was recently explained by increased degradation of 
triacylglycerols (TAGs), resulting in accumulation of the polyketide precursor acetyl6CoA 
223. Additionally, phospho6sugars inhibit antibiotic production in streptomycetes. This effect 
is mediated by the phosphate6 rather than of the glyco6moiety, as the inactivation of phoP 
or ppk prevents or enhances, respectively, their utilization as nutrient sources and their 
inhibitory effect on antibiotic production224. 
 Thus, it is becoming evident that the conventional understanding of the PhoRP, 	
AfsR and GlnR as the elements of the linear transduction systems regulating primary and 

secondary metabolism have been revised significantly over the last several years. Recent 
discoveries made it possible to understand, at least partially, the cross6talk occurring 
between regulators for phosphate and nitrogen metabolism, and to a lesser extent carbon 
metabolism in streptomycetes. It is a reasonable expectation to predict that established 
methods for assessing DNA binding in vivo (i.e. ChIP6seq 225 in combination with new 
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strategies for robustly mutagenizing and identifying mutants (i.e. Tn6Seq 226 will enhance 
the ability to probe these regulons and their cross regulation. 
 
7. THE IMPACT OF METALS ON SECONDARY METABOLISM 	
Iron is an essential metal that plays important roles in DNA replication, protein synthesis 

and respiration. Iron is relatively unavailable in the soil due to the low solubility of the Fe3+ 	
ion under aerobic conditions at neutral pH. Production of iron6chelating compounds called 	
siderophores is the most common way that bacteria circumvent this problem 227. 	
Moreover, some bacteria have developed systems that allow them to utilize siderophores 	
synthesised by neighbouring microorganisms 171, 228, 229. The primary impact of iron 	
deficiency in Streptomyces and other bacteria, is the stimulation of siderophore 	
production. All Streptomyces species examined thus far appear to harbour a BGC for 	
desferrioxamine, which has been proposed to be part of the ‘core’ secondary metabolome 	
of the genus 230, while other streptomycetes produce additional siderophores; S. coelicolor 		
and S. scabies produce coelichelin and pyochelin, for example 231, 232. Production of 	

desferrioxamine is normally repressed by the DmdR1 protein, which becomes 

derepressed in the absence of iron 2336235. The dmdR1 gene is unusual in that its DNA 

sequence encodes a second gene (adm) using the anti6sense strand of DNA 236. Deletion 

of the dmdR1$amd locus in S. coelicolor abolished sporulation and the production of Act 

and Red 233. Subsequent experimentation whereby either dmdR1 or amd were individually 

mutated by a point mutation revealed that inactivation of dmdR1 had no impact on Act and 

Red production where as these compounds were overproduced when only amd was 

mutated 236. Another link between iron availability and secondary metabolism in S. 

coelicolor is that iron de6represses the pleiotropic TCS, AbrA1/A2, which negatively 
	
regulates Act and Red production, although the mechanism has not yet been resolved 237.  


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Zinc is an important transition metal required as a cofactor for many enzymes and 
regulatory proteins important for normal bacteria physiology. However, the intracellular 
free level of this element should be maintained within a narrow range due to its potential 
toxicity 238, 239. Its uptake in streptomycetes as well as in other bacteria is regulated by Zur, 
a zinc6responsive transcriptional regulator 240, 241. Interestingly, there is a Zur6binding site 
within the BGC for the metal chelator, coelibactin and adjacent to this is a binding site for 
another zinc6sensitive regulator, AbsC; together these regulators repress coelibactin 
biosynthesis 242. Interestingly, AbsC also seems to be required for the production of Act 
and Red when S. coelicolor is cultivated under the specific conditions of zinc limitation and 	
inactivation of zur and absC genes block sporulation. Binding of AtrA upstream of the 

promoter for zur 243 has been identified both biochemically and by ChIP6seq (McDowall et 
al, unpubl. data) suggesting yet another layer of regulation that potential facilitates 
integration with primary metabolism as well as secondary metabolism and morphological 
development. More detailed study of these regulators is necessary in order to fully 
illuminate their regulons and the nature in which they overlap and interconnect with other 
metal acquisition systems. Amycolatopsis japonicum produces the biodegradable 
ethylenediame6tetra acetate (EDTA) isomer [S,S]6EDDS, whose gene cluster was 
elucidated 244. Trace amounts of zinc in the culture media inhibit the production of [S,S]6
EDDS, which led to the proposal that the molecule is required for zinc uptake. The 	
synthesis of the zincophore is repressed by the zinc regulator Zur 244.  

Recently, the impact of rare earth elements (REEs) on secondary metabolism was 
explored. Supplementation of culture medium with scandium or lanthanum stimulated the 
production Act by S. coelicolor, Str by S. griseus and actinomycin by S. antibioticus 245. 
Although precise mechanistic detail is lacking, scandium stimulation of Act production is 
dependent on the ppGpp synthetase, RelA and is mediated by upregulation of actII6ORF4 
245. Interestingly, scandium was also able to rescue the ability of S. lividans to produce Act, 
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a compound that the species does not normally produce despite harbouring a nearly 
identical gene cluster 245. Quantitative RT6PCR and HPLC analyses showed that in 
addition to Act, scandium supplementation stimulated the expression of eight other BGCs 	
in S. coelicolor 246. Stimulation of secondary metabolism by REEs is not restricted to 

actinobacteria – scandium was recently shown to elicit the production of amylase and 
bacilysin in B. subtilis 247. Thus, REEs represent a relatively unexplored method for 
activating the expression of silent or weakly expressed BGCs and future studies should be 
aimed at understanding the molecular mechanism(s) by which this occurs. 
 
8. MORPHOLOGICAL DEVELOPMENTAL CONTROL OF ANTIBIOTIC PRODUCTION 
As mentioned in the introduction to this review, the production of antibiotics (and other 
secondary metabolites) is temporally correlated to the onset of development of 
Streptomyces colonies 31, 33. A model of the linkage between the control of antibiotic 	
production and development is presented in Fig. 5. A likely explanation is that the colony is 

particularly vulnerable to competitors when it is undergoing programmed cell death (PCD), 
and antibiotics are produced to protect the colony and the nutrients released during PCD. 
Until recently, the occurrence of PCD in bacteria has been a subject to major debate, but it 
is becoming increasingly clear that PCD plays a major role the life cycle of multicellular 
bacteria 22, 2486250, and in that of streptomycetes in particular 251, 252. A direct link between 
PCD and antibiotic production was demonstrated with the discovery that GlcNAc, which 
together with N6acetylmuramic acid forms the peptidoglycan strands, acts as an elicitor of 
antibiotic production via metabolic inactivation of the global antibiotic repressor DasR 194, 
253. For details we refer to section 5. Interestingly, production of prodiginines, which have 	
anticancer activity by degrading the DNA, may play a direct role in triggering PCD in S. 

coelicolor, and mutants that fail to produce prodiginines have strongly reduced PCD, 
whereby vegetative growth is prolongued 254. 
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 As a consequence of the growth phase6dependent control of antibiotic production, 
developmental mutants that are blocked in an early phase of the life cycle 6 in particular 
bld mutants 6 typically fail to produce antibiotics. As mentioned in Section 5.1, mutants of 
the developmental gene bldB are not only disturbed in development and antibiotic 
production, but are also defective in CCR 187, 188. This links the pathways that regulate 
carbon utilization and morphological differentiation. BldB is a member of a family of DNA6
binding proteins that are only found in Actinobacteria. The family is widespread in 	
streptomycetes, with several paralogues in S. coelicolor, including AbaA and WhiJ, which 

play a role in the control of antibiotic synthesis and development, respectively 189. 
Identification of the BldB regulon and the way its activity is modulated will likely offer 
important new insights into the growth phase6dependent control of antibiotic production 
and the role of CCR in this process. 
BldD is a small DNA6binding protein that is required for development and antibiotic 
production (Fig. 5) 255. BldD is related to SinR, a master regulator of the transition from the 
motile to a sessile state in Bacillus subtilis, and hence associated with the control of biofilm 
formation 256, 257. The BldD regulon encompasses over 150 transcriptional units, many of 
which are involved in the control of development 258. One of its targets is bldA, which at 	
least in part explains the requirement of BldD for antibiotic production. BldD binds to DNA 

as a homodimer, and dimerization is dependent on the binding of a tetramer of the 
signalling molecule cyclic6di6GMP 259. This is another interesting example of small 
molecule6based control of antibiotic production in Streptomyces. 
Other bld mutants also fail to produce antibiotics, but the phenotype of these 
mutants is not independent of the growth medium (Fig. 5). In fact, bldA, bldC. bldG, bldH 
(adpA), bldJ and bldK mutants produce spores on non6repressing carbon sources such as 
mannitol or glycerol, but not on media containing glucose. Interestingly, mutation of glkA 
restores antibiotic production and morphological development to bldA mutants 33, while 
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bldJ and bldK mutants are rescued by supplementing the colonies with iron. The latter is 	
due to their failure to produce the siderophore desferrioxamine 170. In fact, most bld 

mutants are affected in desferrioxamine biosynthesis, with strongly reduced production of 	
the siderophore in bldA, bldJ, and ptsH mutants, and overproduction in bldF, bldK, crr and 	
ptsI mutants 170.  	
 An infamous example of translational control of development and antibiotic 	
production is BldA, the tRNA that recognizes the rare UUA codon for leucine. Mutants of 	
S. coelicolor defective in bldA have a bald phenotype and fail to produce antibiotics 260, 261. 	
The latter is a direct consequence of the presence of UUA codons in the mRNA of the 	
genes for ActII6ORF4 and RedZ 73, 74. The presence of TTA codons in BGCs for 	
specialized metabolites 6 and in particular in genes encoding CSRs 6 is more a rule than 		
an exception, which provides strong phylogenetic evidence for the fact that control of 	

antibiotic production by BldA has evolved with a purpose 262.  

Mutants that are blocked in sporulation (so6called whi mutants) generally are not 

affected in antibiotic production. This is most likely because the decisions to switch on 

secondary metabolism made at an earlier stage in the life cycle. The exception is ssgA, 

whose transcription does not depend on any of the 'classical' whi genes 207. SsgA 

activates sporulation6specific cell division by controlling the localization of its paralogue 

SsgB, which in turn recruits FtsZ to initiate sporulation6specific cell division (Fig. 5) 263. In 

contrast to most developmental control proteins, SsgA and SsgB lack DNA6binding 

domains. The SsgA6like proteins are unique to sporulating actinobacteria, and most likely 
	
function as chaperones that recruit multi6component complexes 264, 265. Over6expression of 


ssgA results in overproduction of prodiginines (Red), while Act production is blocked 266, 
267. The most likely explanation is that SsgA blocks S. coelicolor development at a stage 
corresponding to early aerial growth, where Red production has been switched on, while 
Act production has not yet been initiated. SsgA and SsgB probably represent another 
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important link in the coordination of secondary metabolite production with vegetative 
growth 268.
WblA is a member of the WhiB6like proteins, and 11 paralogues are encoded by the 
S. coelicolor chromosome 269. The Wbl proteins are small iron6sulphur proteins that are 
unique to actinobacteria. Disruption of wblA has a highly pleiotropic effect on overall gene 	
expression in S. coelicolor and prevents development while strongly increasing antibiotic 

production in this organism 269. Conversely, overproduction of WblA pleiotropically 
represses the biosynthesis of Act, Red and Cda in S. coelicolor and of anthracyclines in S. 
peucetius 270. Deleting wblA also results in enhanced production of specialized metabolites 
in other streptomycetes, such as Streptomyces ansochromogenes, Streptomyces 
glaucescens, Streptomyces roseosporus and Streptomyces sp. C4412 as well as in 
Pseudonocardia 2716276, and should therefore be considered as a general approach to 
achieve enhanced production of cryptic antibiotics in a given strain. It is yet unclear how 
WblA controls antibiotic production. 
 	
9. AUTOREGULATORS AND THE CONTROL OF ANTIBIOTIC PRODUCTION 

Bacteria communicate with each other through production of small extracellular molecules, 
called bacterial hormones or autoregulators. After the discovery of the gamma6
butyrolactone A6factor (26isocapryloyl63R6hydroxymethyl6γ6butyrolactone), produced by S. 
griseus, many more bacterial hormones have been identified, such as GBLs similar to A6
factor, furans, gamma6butenolides and PI6factor. In general, these signalling molecules 
are active in nanomolar concentrations and diffuse readily from one actinomycete to 
another, thereby affecting development and antibiotic production. GBL production is most 
likely not species6specific, as different species can produce the same GBL, suggesting 
extensive interspecies communication and 'eavesdropping'. Antibiotics may also function 	
as signalling molecules, thereby induce antibiotic activity and/or resistance, and again in a 

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more general fashion, affecting a broad range of hosts. Thus, the usage of bacterial 
hormones or antibiotics is an important factor in the discovery of novel antibiotics, as well 
as co6culturing micro6organisms (recently reviewed in 277). 
 
9.1. The gammabutyrolactone regulatory system in 	 and 
	  
Enzymes responsible for the synthesis of gamma6butyrolactones (GBLs) in 
streptomycetes are identifiable through their homology to the A6factor synthetase AfsA of 
S. griseus 91. The orthologue of AfsA is encoded by scbA (SCO6266) within the cpk gene 
cluster responsible for the production of the yellow compound coelimycin P1 278. ScbA is 	
required for the production of the GBLs of S. coelicolor. This strain produces 8 different 

GBLs (SCB168). The structure of these molecules have recently been solved after they 
were overproduced in the super host M1152 279. Deletion of scbA resulted in the 
overproduction of Act and Red biosynthesis and reduced cpk expression 280 Divergent to 
scbA lies scbR (SCO6265), which encodes a transcription factor that appears to activate 
transcription of scbA as well as a repressor of its own transcription and that of cpkO 
(kasO), which encodes the CSR of the coelimycin BGC cluster, provided GBL is not bound 
by ScbR 142, 141. It also positively regulates CdaR, the CSR of the Cda BGC. Deletion of 
scbR resulted in reduced Act, Red and Cda production and increased coelimycin P1 
production 143. The regulation of scbA is complex, with no fewer than five scbR paralogues 	
in S. coelicolor 277, one of which scbR2 (SCO6286) is also encoded within the coelimycin 

BGC 281. The reader is referred to our previous review for more details 33. 
ScbR2 is highly similar to ScbR, but unlike ScbR it is not able to bind GBLs, and is 
hence considered a pseudo gamma6butyrolactone receptor 278, 282. Instead it binds the 
endogenous antibiotics Act and Red and the exogenous antibiotic jadomycin B and related 
angucyclines 278, 283. Interestingly, addition of non6endogenous jadomycin B from S. 
venezuelae releases ScbR2 from the promoters of redD and adpA in S. coelicolor, leading 
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to accelerated Red production and morphological differentiation. ScbR2 probably has a 
greater effect on secondary metabolism than ScbR. Deletion of scbR2 abolishes Act, Red 
and Cda production and induced coelimycin production 281, 283. Like ScbR, ScbR2 directly 	
represses cpkO 278. ScbR2 is also a repressor of scbA, and acts both directly and 

indirectly on antibiotic production 282. ChIP6seq showed that ScbR and ScbR2 have many 
shared targets genes related to primary and secondary metabolism 143, 284. Both directly 
act on afsK and on genes involved in malonyl6CoA synthesis and hence precursor supply 
for polyketide natural products. Interestingly, the TetR6like proteins ScbR and ScbR2 can 
also bind as heterodimers, and co6immunoprecipitation of ScbR2 and ScbR revealed that 
only the ScbR6ScbR2 heterodimer can control SCO5158, which encodes an 
uncharacterized protein 285. Such heterodimer formation is not unique, and was previously 
proposed for the gene products of mmfR and mmyR of the methylenomycin BGC 286. 
S. avermitilis contains three GBL6like receptors encoded by genes that are located 	
in a single locus, namely aveR1, aveR2 and aveR3. This locus also contains the genes 

aco and cyp17 required for avenolide biosynthesis. The bacterial hormone avenolide 
increases avermectin production in a dose6dependent manner when added in nanomolar 
concentrations to an aco deletion mutant 287. The AveR1 protein was identified as its 
cognate receptor 288. Deletion of aveR1 or addition of avenolide did not influence 
avermectin production, but increased avenolide production. An explanation for the latter 
might be that the threshold that is required for avermectin production has already been 
reached at the start of growth. This led to the suggestion that AveR1 acts as a repressor in 
the early stages of growth 289. AverR1 represses its own transcription and that of aco 289.  
AveR2 is a pseudo GBL6receptor that represses the transcription of aveR, encoding 	
the positive CSR of the ave cluster 290. Additionally, AveR2 represses aco and cyp17, and 

controls genes involved in primary metabolism, ribosomal protein synthesis and stress 	
responses. Such an extended regulon is reminiscent of ScbR2 (see above), and it is 	
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important to note that both regulators can bind endogenous and exogenous antibiotics. 	
Indeed, the affinity of AveR2 for DNA is influenced by avermectins and also by the 	
exogenous antibiotics jadomycin B and by aminoglycosides. Thus, we note that such 	
pseudo6GBL receptors should be considered as important pleiotropic regulators 290.  	
AveR3 shows similarity to autoregulator receptors and activates aveR transcription 	
of the avermectin BGC, and indirectly also filipin biosynthesis 291, 292. Interestingly, deletion 	
of aveR3 resulted in the discovery of the cryptic natural product, phthoxazolin A, a 		
cellulose synthesis inhibitor that shows activity against plant pathogenic oomycetes. The 	

fact that GBL6mediated regulatory systems control cryptic genes in both S. coelicolor and 

S. avermitilis makes them candidate targets for drug discovery. 

 

9.2. GBLreceptors and antibiotic production in other streptomycetes 

The examples of S. coelicolor and S. avermitilis suggest that the presence of genes for 

GBLs and their receptor proteins may serve as beacons for cryptic BCGs. Similarly, the 

BGCs for the angucyclines jadomycin B (from S. venezuelae) and auricin (from S. 

aureofaciens) and also contain genes for GBL synthases and their cognate receptors 293, 

294. The gene jadR3 harboured within the jadomycin B BGC encodes a putative GBL 
	
receptor located upstream of the GBL synthase genes jadW123. The product of this GBL 


synthase system is SVB1, which is identical to the GBL SCB3, produced by S. coelicolor. 	
In S. venezuelae, only JadW2 is required for jadomycin production 294. Nevertheless, 	
deletion of jadW1 abolishes both jadomycin B and chloramphenicol production under 	
conditions that are known to be favourable for production of these antibiotics 295. JadR3 is 	
an autorepressor and also represses jadW1 transcription, and thereby represses 	
jadomycin B production 294. The auricin BGC of S. aureofaciens is controlled by the GBL 	
synthase SagA and its cognate receptor SagR, and again the genes encoding these 	
proteins are located directly next to the biosynthetic genes. Deletion of sagR results in 	
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early but reduced auricin production, while deletion of sagA abolishes auricin production, 		
establishing their key role in controlling auricin biosynthesis. In contrast to other GBL 	

receptor proteins, SagR does not auto6regulate its own transcription, but instead sagR and 	
sagA are repressed by the CSR Aur1R 293. 	
Further on the theme, the production of indigoidine (a blue6pigmented compound), 	
of nucleoside antibiotics (showdomycin and minimycin) and of D6cycloserine by S. 	
lavendulae FRI65 is controlled by the bacterial hormone IM62 and its cognate receptor 	
FarA 296, 297. Supplementation of culture media with IM62 enhances production of 	
indigoidine, but abolishes production of D6cycloserine 296. FarA inhibits its own expression 	
and activates the expression of FarX, the protein required for IM62 biosynthesis. The 	
genes encoding FarA and FarX are located on a regulatory island spanning 12.1 kb 298. 		
This island contains the genes farA$E, farR1$5 and farX 298. FarA negatively regulates its 	

own expression and the expression of farR1 (which encodes an orphan response 	
regulator), farR2 (for a pseudo6GBL receptor), farR4 (for a SARP regulator) 299, farB (for a 	
structural protein) 298. Since farR3 and farR4 can be transcribed both as monocistronic and 	
bicistronic mRNA, it appears that farR3 is also a target of FarA 299. FarR2 is a pseudo6GBL 	
receptor that positively regulates the production of indigoidine, but negatively regulates the 	
expression of the far regulatory genes in the regulatory island, including the expression of 	
farX 300. Similarly, FarR3 positively regulates the production of indigoidine 299, but in both 	
cases the control is most likely indirect 300, 301. The SARP regulator FarR4 represses IM2 	
biosynthesis 299. which offers a unique example of a SARP regulator that acts at the front 		
instead of the end of a regulatory cascade 299.  	

The complex regulatory network of the “pristinamycin supercluster” of S. 	
pristinaespiralis is also under the control of a GBL6receptor. Pristinamycin is a mixture of 	
two compounds, including the cyclohexanedepsipeptide pristinamycin I (PI) and the poly6	
unsaturated macrolactone pristinamycin II (PII) that are produced in a 30:70 ratio. The 	
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mixture of pristinamycin is significantly more active against pathogenic bacteria than PI 	
and PII separately 302. PI is synthesized by non‐ribosomal peptide synthetases (NRPS) 	
and PII by hybrid polyketide synthases (PKS)/NRPS 303. The genes required for PI and PII 	
production are not arranged in a single BGC, but are heterogeneously divided over a 210 	
kb genomic region whereby the biosynthetic genes are interspersed by a cryptic BGC 303. 		
These characteristics of the BGC and the fact that the cluster contains seven genes 	

encoding CSRs makes the regulation of pristinamycin biosynthesis very complex 304. 	
These CSRs include the GBL6receptor SpbR, two TetR6like regulators (PapR3 and 	
PapR5), three SARP regulators (PapRI, PapR2, PapR4) and a response regulator 	
(PapR6) 303, 304. The regulatory cascade starts with the release of SpbR from the DNA 	
when its ligand reaches a critical concentration 304. The pristinamycin BGC is under the 	
direct control of the SARP regulators PapR1, PapR2 and the response regulator PapR6 	
304. PapR2 is most likely the master regulator of the pristinamycin BGC, as this is the only 	
regulator that is fully required for pristinamycin biosynthesis 304. The regulatory genes that 	
directly control the pristinamycin BGC are repressed by the TetR6regulator PapR5 304,305. 		
PapR5 shows similarity to pseudo6GBL receptors, suggesting that perhaps pristinamycin 	

and/or biosynthetic intermediates act as ligands for PapR5 and may thereby control the 	
level of pristinamycin 304. Similar as to other regulatory networks, the GBL6receptor is not 	
the first regulator in the regulatory cascade, since SpbR is positively regulated by an AtrA 	
(SSDG_00466) regulator outside the BGC. AtrA in turn positively controls the transcription 	
of PapR5 305. Thus, the pristinamycin BGC is subject to complex and multi6level control, 	
several elements of which deserve further investigation, so as to unravel the full regulatory 	
network. 	
 	
10. EMERGING THEMES IN THE CONTROL OF ANTIBIOTIC PRODUCTION IN 		
ACTINOBACTERIA 	

Page 34 of 81Natural Product Reports
35 
 
Besides the usual suspects, less well6studied genera of Actinobacteria (often referred to 	
as rare Actinobacteria) also produce a wide range of natural products, and insights into 	
their molecular regulation is important from the perspective of drug discovery and 	
production improvement. Culture collections housed by biotechnology companies and 	
research institutes possess several rare Actinobacteria, including Micromonosporaceae, 	
Streptosporangiae, Pseudonocardiaceae, Nocardiaceae, and Thermomonosporaceae, 	
and many other rare and unclassified species that have yet to be explored 3066309. In 	
recent years, interest in strains isolated from marine environments and other ecological 	
niches such as plants and insects has grown because they offer a rich new microbial 		
source for NP discovery 35, 310, 311. The regulation of natural product biosynthesis by rare 	

Actinobacteria is poorly characterised, because many of them are genetically intractable 	
and limited genetic tools are available. As the cell wall structure between Actinobacteria 	
often varies and is different from that of streptomycetes, preparation of protoplasts (and 	
regeneration) typically requires different methods 312. A protocol to prepare protoplasts of 	
Planobispora rosea, the producer of the thiazolyl peptide antibiotic GE2270 that targets 	
elongation factor EF6Tu 313 was applied to different rare Actinobacteria312. This protocol 	
demonstrated the applicability of both lysozyme and mutanolysin (from S. globisporus) to 	
produce protoplasts from these industrially important strains 312. Other issues that need to 	
be solved for genetic manipulation of rare actinobacteria include identification of suitable 		
origins of replication for plasmidsthe methylation pattern of the DNA 315, 316 and the use 	

of specific promoters for expression 317, 318. Many of these technical difficulties can in 		
principle be circumvented by the use of expression of a BGC in a heterologous host. 		
Expression of the BGC for GE2270 of P. rosea in S. coelicolor M1146 allowed the study of 		
its regulation 319. Deletion of pbtR ,encoding a TetR6family regulator, abolished the 		
production of GE2270. Similarly, the BGC for taromycin A from Saccharomonospora sp. 		
CNQ490 was also expressed in S. coelicolor M1146 to allow its genetic manipulation. 		
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Deletion of tar20, encoding a LuxR regulator of the taromycin BGC, increased the 		
production of the compound in the heterologous strain 320. Heterologous expression of a 		
BGC may often be suitable to study the function of CSRs within a BGC, but for 			
understanding of the global regulatory network and the ecological responses that control 		

the BGC of interest, it is necessary to study the BGC in its natural host. In a number of 	

Actinobacteria, the molecular regulation of antibiotic production has been studied. 	

Especially in strains that produce clinically important antibiotics, such as glycopeptide 	

producers. It appears that the rare Actinobacteria that have been studied indeed contain 	

similar regulators as Streptomyces and therefore we expect that most of the control 	

mechanisms of antibiotic production are similar. Below the control of antibiotic production 	

in a number of Actinobacteria is discussed and compared to that of Streptomyces.  	

 	

10.1. Control of glycopeptide biosynthesis 	
	
The glycopeptide antibiotics vancomycin and teicoplanin are important last line of defence 	


antibiotics that are used to treat infections associated with multi6drug resistant Gram6

positive bacteria 321 322. Their target is the peptidoglycan precursor lipid II, thereby 

inhibiting synthesis of the bacterial cell wall 323. Vancomycin is produced by Amycolatopsis 

orientalis and teicoplanin by Actinoplanes teichomyceticus 324, 325. Other well6studied 

members include the precursor of dalbavancin, A40926 produced by Nonomuraea sp. 

ATCC39727 326, balhimycin produced by Amycolatopsis balhimycina 327, and the 

sugarless glycopeptide A47934 produced by S. toyocaensis 328. A comparison of the 

BGCs for these compounds (tei for teicoplanin, bal for balhimycin and dbv for A40926) 

and their control is presented in Fig. 6. Members of the glycopeptides share a 
	
heptapeptide core, which is synthesized by non6ribosomal peptide synthetases (NRPS), 


with further modifications such as cross6linking, methylation, halogenation glycosylation 

or attachment of sulphur groups 322, 329. Glycopeptides bind to the D6alanyl6D6alanine(D6

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ala6D6ala) terminus of the growing lipid attached peptidoglycan chain on the outside of the 

cytoplasmic membrane and thereby prevent the binding of transpeptidases that create 

the cross6links between the polysaccharides, required for cell wall integrity 323.  

The BGCs of these antibiotics are typically controlled by CSRs of the StrR and 

LuxR families 3306332. The teicoplanin BGC spans 89 kb and includes five regulatory genes, 

tei2, tei3, tei15*, tei16* and tei31* 324, 325. Tei2 and Tei3 show high homology with the 

VanR/VanS system of S. coelicolor 333, 334 and are involved in the control of teicoplanin 
	
resistance. The genes tei15* and tei16* encode members of the StrR and LuxR family 


regulators, respectively. Overexpression of Tei15* results in 306406fold increase in 

teicoplanin biosynthesis 332, 335. Tei15* is the primary CSR, and directly controls the 

transcription of the regulatory genes teiA for the NRPS module, tei2* (which encodes a 

deacetylase), tei16*, tei17* involved in Dpg synthesis and tei27* (for an unknown protein). 

Tei15* also controls the expression of the LuxR family regulator Tei16* and the SARP 

family regulator Tei31*. The targets of Tei16* and Tei31* in the teicoplanin cluster remain 

unknown, although Tei16* does positively control teicoplanin production 332. Tei15* does 

not show autoregulation, in contrast to its orthologue BbR in the balhimycin BGC 331, 332. 

See Fig. 6.  
	
The dalbavancin BGC of Nonomuraea sp. ATCC39727 contains four regulatory 


genes, namely dbv3, dbv4, and the TCS dbv6 and dbv22 for the control of resistance (Fig. 

6). Dbv4 (similar to StrR and Tei15*) is the likely CSR, and is expressed under phosphate6

limiting conditions, while Dbv3 is a LuxR6type regulator similar to Tei16*. Both Dbv3 and 

Dbv4 are required for A40926 production 330. Dbv3 controls the transcription of dbv4, as 

well as genes for the biosynthesis of 46hydroxyphenylglycine, the heptapeptide backbone, 

and for glycosylation and export. However, similar to the situation for Tei16* in the 

teicoplanin BGC, no common regulatory elements were identified in the promoter regions 

of the Dbv36controlled genes, and control could therefore be indirect 330. Dbv4 is directly 

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involved in the regulation of genes involved in 3,56dihydroxyphenylglycine, cross6linking, 
	
halogenation, glycosylation and acylation 330. Dbv4 and the Dbv4 regulon are repressed by 


phosphate, whereas Dbv3 and its regulon are not. No Pho6boxes were identified upstream 

of the dbv4 genes, suggesting the phosphate repression is indirect 336. 

The glycopeptide balhimycin is produced by Amycolatopsis balhimycina (formerly 

Amycolatopsis mediterranei). The balhimycin BGC has a simpler control system with three 

regulatory genes, namely the VanR/VanS TCS for resistance and the StrR6like regulator 

Bbr (Fig. 6). Bbr binds to a consensus sequence (GTCCAR(N)17TTGGAC) that is found 

within the promoter for its own transcription, the putative ABC transporter gene tba, oxyA 

for a P450 monooxygenase, dvaA involved in dehydrovancosamine synthesis and the 

putative sodium proton antiporter gene orf7 331. In the three glycopeptide BGCs the StrR 
	
CSR binds to the consensus sequence that is conserved in the intergenic regions of the 


glycopeptide BGCs, although the target sequence may vary and deviate from the 

consensus 329, 331, 332, 336. Although these three BGCs are organised in a similar manner 

and contain regulatory genes, the mechanism of regulation differs between them, and 

therefore making assumptions about the regulatory network based on bioinformatics alone 

is not sufficient 330. In S. griseus, StrR is positively controlled by the pleiotropic regulator 

AdpA. However, overexpression of the putative adpA gene of A. balhimycina did not 

induce antibiotic production, although heterologous expression of this regulator in S. 

coelicolor, S. ghanaensis and several soil Actinobacteria was successful 337. Vancomycin 

biosynthesis and its control are well understood, but the role of StrR regulator in the BGC 
	
(AORI_1475) has not been elucidated


Since most glycopeptide BGCs contain a StrR6like positive regulator, over6

expression of the corresponding gene is a logical generic strategy to induce the 

expression of (cryptic) glycopeptide BGCs. A good example is the production of ristomycin 

A in Amycolatopsis japonicum. This strain is known for the production of (S,S)6

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ethylenediamine disuccinic acid [(S,S)6EDDS], the biodegradable isoform of EDTA 

(section 7) . Under standard laboratory conditions this strain does not produce antibiotics, 

but over6expression of the StrR orthologue in A. japonicum induced the production of 

ristomycin A, which is used for the diagnosis of von Willebrand disease and Bernard6

Soulier syndrome 338. 
	
 


10. 2. Control of glycopeptide resistance  

Bacteria that are resistant against glycopeptide antibiotics replace the D6alanine for D6

lactate as the terminal residue of the peptide chain of the peptidoglycan. As the affinity of 

the glycopeptide for the latter is a lot lower than for D6ala6D6ala, binding of the 

glycopeptide is prevented 339, 340. The glycopeptide BGCs contain genes that encode 

homologues of the VanR/VanS TCS that governs glycopeptide resistance.  

S. coelicolor is resistant against vancomycin and this resistance is conferred by 

genes that are similar to the ones present in vancomycin resistant enterococci 333, 334. The 

resistance cluster of S. coelicolor is organized in four transcription units, namely vanRS, 
	
vanJ, vanK and vanHAX. The latter encode the enzymes required for biosynthesis and 


incorporation of D6lac in the peptide moiety of the PG. All transcription units are regulated 
	
by VanRS 333. Binding of vancomycin by the N6terminal part of VanS leads to its 
	
autophosphorylation, and this phosphate is then transferred to the N6terminal receiver 
	
domain of VanR, thereby activating its C6terminal DNA binding effector domain. This 
	
results in expression of the resistance genes. In the absence of vancomycin VanS acts a 
	
phosphatase that dephosphorylates VanR, and hence vanS mutants show constitutive 
	
expression of vancomycin resistance 334, 341. In contrast, deletion of vanS in S. 
	
toyocaensis results in sensitivity to A47934, and it was suggested that VanR of S. 
	
coelicolor is phosphorylated by other proteins while that of S. toyocaensis is not 342. 
		
Interestingly, the VanRS TCS is an important determinant of the species6specific 
	

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glycopeptide resistance profile. S. coelicolor is resistant against vancomycin and A47934, 


but sensitive to teicoplanin, while S. toyocaensis is only resistant against A47934 8. 


Exchanging the VanRS TCSs between the two Streptomyces strains is sufficient to switch 


the resistance profile 8. Surprisingly, expression of the VanR orthologue of A. balhimycina 


(VnlR) in S. coelicolor even governed resistance to teicoplanin, and led to increased 


actinorhodin biosynthesis 343. VnlR controls vanHAX in S. coelicolor, despite the fact that 


it does not control vanHAX in A. balhimycina itself 343. 


 


10.3. σfactor/antiσfactor systems and the control of antibiotic biosynthesis 

	
An important new element of antibiotic control that was discovered in recent years is the 



control by σ6factors, the subunits of the RNA polymerase responsible for promoter 
recognition. An important example is that of the control of lantibiotics. Lantibiotics are 
ribosomally synthesized, post translationally modified peptide antibiotics (RiPPs; 344). The 
best known lantibiotic is the food6preservative nisin, produced by Lactococcus lactis and 
discovered as early as 1928 345. Lantibiotics are synthesized as a prepropeptide encoded 
by a precursor gene generally referred to as lanA. This propeptide is post6translationally 
modified via intramolecular lanthionine bridges that are formed between unusual amino 
acids to yield the mature peptide 346. Nisin and several other lantibiotics target the 
pyrophosphate linkage component of the cell6wall precursor lipid II. As this target is 	
different from that of the clinically used antibiotic vancomycin, there is no cross6resistance 

with glycopeptides, making them interesting new antibiotics for the treatment of methicillin 
resistant Staphylococcus aureus (MRSA) and vancomycin6resistant enterococci (VRE) 347. 
Screening a library of 120,000 chemical extracts derived from 40,000 Actinobacteria for 
activity against cell6wall biosynthesis by Vicuron Pharmaceuticals identified five novel 
lantibiotics, including microbisporicin (also known and NAI6107) and planosporicin, 
produced by Microbispora corallina and Planobispora alba, respectively 348, 349. The control 
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of the BGCs for microbisporicin (mib in M. corallina and mlb in M. ATCC6PTA65024) and 
for planosporicin (psp) have been studied in detail 3506352. The BGCs have a gene for an 
extracytoplasmic function (ECF) σ6factor /anti6 σ6factor complex (MibX/MibW for 	
microbisporicin and PspX/PspW for planosporicin). ECF σ factors mediate responses to 

extracellular signals and stress or steps in morphological differentiation 353, 354, but their 
involvement in the control of antibiotic production was only recognized recently. The 
microbisporicin and planosporicin BGCs also contain a gene for a regulator with a LuxR6
like C6terminal domain. Herein, we use microbisporicin biosynthesis as the example for 
both BGCs, see Fig. 7 for an overview of its control. The BGC is controlled by its own 
production by a feed6forward mechanism: deletion of mibA results in decreased 
transcription of the other mib genes, while growth of mibA mutant colonies adjacent to 
wild6type microbisporicin6producing colonies restored mib transcription 351, 352, 355. This 
effect is specific, since microbisporicin cannot induce the production of planosporicin by 	
Planobispora alba 351. The mib cluster includes six transcription units, for synthesis, 

modification, proteolysis, export, immunity and regulation, and all except the mibA 
structural gene contain the ECF σ6factor promoter motif (GACC6N156GCTAC) that is 
recognized by MibX 350, 352, 355 (Fig. 7). The promoter of mibA is controlled by MibR; in turn, 
transcription of mibR depends on MibX and is enhanced by the stringent response. 
Indeed, deletion of relA in M. corallina abolishes microbisporicin production. Thus, a 
complex regulatory network ensures the correct timing of microbisporic biosynthesis, 
which is induced by both nitrogen starvation and the ensuing stringent response, which 
activates MibR expression and hence the expression of the (non6toxic) precursor peptide. 
This precursor is then exported and processed to yield the active antibiotic 350. Under 	
repressing conditions, MibX is recruited by the membrane bound anti sigma factor MibW, 

thereby shutting down the biosynthetic pathway. Microbisporicin production also directly 
depends on the developmental programme, with reduced expression in bld mutants, 
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similarly to the biosynthesis of the morphogenic lantibiotic6like morphogen SapB in S. 
coelicolor 356. For a detailed overview on the regulation of RiPPs in Actinobacteria and 
other bacterial genera, we refer the reader a recent review 357. 
Involvement of σ factors in the control of antibiotic production is not exclusive to 
lantibiotic BGCs. SigT regulates Act production in S. coelicolor via relA in response to 
nitrogen starvation, which links nitrogen stress to secondary metabolism 358. In S. albus, 
the ECF σAntA controls the synthesis of the antimycin precursor, 36formamidosalicylate 359, 	
360, and σ25 differentially controls the biosynthesis of oligomycin and of the important anti6

helminthic drug avermectin in S. avermitilis 361. Antimycin is a mitochondrial cytochrome c 
reductase inhibitor produced by diverse actinobacteria. σAntA was the first example of 
regulation of antibiotic production by a cluster6situated ECF σ factor in S. species and it 
was recently shown that this is likely to be a conserved strategy of regulation for more than 
70 antimycin BGCs 362. Unlike other ECFs, which are controlled by an anti6σ factor that is 
unable to maintain an inactive complex in the presence of cognate stimulus, σAntA is an 
orphan and is not controlled by such a factor. Instead, evidence to date suggests that σAntA 
is controlled by Clp proteolysis 359. The involvement of σ6factor genes in the control of 
antibiotic production is a new concept, and in particular the presence of σ factor genes 	
within BGCs may function as beacons to identify BGCs in genome mining. 

 
10.4. Regulation of antibiotic production in 
	

Recently, studies have also been dedicated to the regulatory network of natural product 
biosynthesis in the marine actinomycete Salinispora. Salinispora is an obligate marine 
actinomycete and most of the isolates are derived from marine sediments. The genus 
knows three different species, under which S. pacifica, S. tropica and S. arenicola 363. The 
compounds that were discovered from this genus are predominantly new and therefore 
this genus is a good example of the concept that new genera derived from remote areas 
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are a good source for the discovery of novel natural products 363.  One of these studies 	
reveals that in S. tropica CNB6440, a LuxR6type regulator positively regulates the 

biosynthesis of the important natural product salinisporamide A, a proteasome inhibitor 
that is in stage 1 of clinical trials of anti6cancer treatment. This regulator controls the genes 
involved in the biosynthesis of the salinisporamide A precursor chloroethylmaloyl6CoA, 
and thereby specifically regulates the production of salinisporamide A and not of other 
salinosporamides that are produced by S. tropica CNB$440 364.  
In the genus Salinispora an important concept for the study of cryptic gene clusters 
was revealed 365. Transcriptomic comparison of the Salinispora strains S. pacifica CNT6
150, S. tropica CNB6440, S. arenicola CNS6205 and S. arenicola CNS6991 revealed that 
BGCs common between different strains are not necessarily controlled in the same way 	
and could be active in one while silent in another. Such strain6specific silencing of a BGC 

was explained by mutation of regulatory genes. Indeed, an orphan BGC in S. pacifica 	
(STPKS1) was expressed normally, while its counterpart in S. tropica was silent due to the 	
lack of the AraC6family CSR, which was replaced by a transposase. Interestingly, this 	
silent gene cluster is conserved throughout the S. tropica clade, which suggests that either 	
this BGC is permanently silenced or that another regulator is involved in the control of the 	
BGC. The BGC for the enediyene PKS1A was silent in CNS6991 and expressed in CNS6	
205. Comparative genomics and transcriptomic data revealed that a σ factor upstream of 	
the BGC was expressed in S. arenicola CNS205, but not in CNS991. Differential 	
expression of this σ factor was proposed be a consequence of its different chromosomal 		
location in the two strains. The BGC for the black spore pigment was present in all four 	

Salinispora strains, but the full BGC was only expressed by S. tropica CNB6440 and S. 

pacifica CNT6150, whereas only a subset of the genes within the gene cluster was 

expressed in the two S. arenicola strains. The spore pigment BGCs that were entirely 

expressed contained one or two luxR genes, whereas the partially expressed BGC 

Page 43 of 81 Natural Product Reports
44 
 
contained small genes encoding hypothetical proteins of unknown function. The sta gene 

cluster for staurosporine was also differentially expressed between the four Salinispora 

strains, but all strains contained the malT gene for the CSR. Finally, the fact that a BGC 

(NRPS4) was expressed in S. arenicola and S. pacifica, but not in S. tropica was 

explained by the lack of a xenobiotic response element in S. tropica 365. Further genetic 
	
analysis of these interesting examples is required to fully understand the regulatory 


mechanisms for these BGCs. The differential expression of gene clusters between 
different species suggests that one feasible approach to the problem of silent gene 
clusters may be to look for the same (or highly similar) gene cluster in related 
actinobacteria, and see if the cluster is expressed there. With the ever6growing genome 
sequence information, this approach is becoming increasingly feasible, and is particularly 
attractive in strains that are not genetically tractable.  
 
10.5. Regulation of rifamycin biosynthesis in 
		
 
Recently, the molecular regulation of the rifamycin BGC was studied in Amycolatopsis 	
mediterranei. Although rifamycin and its derivatives are the first6line anti6tuberculosis 

drugs, the regulation of the rifamycin BGC was only studied recently. Deletion of glnR 
influences the biosynthesis of rifamycin, although this control is indirect 366. The LuxR6type 
regulator RifZ, encoded by the last gene in the gene cluster, positively controls all of the 
operons in the rifamycin BGC 367. The rifamycin BGC also encodes a TetR6family 
repressor (RifQ), which represses rifamycin biosynthesis and efflux. Deletion of rifQ 
resulted in increased production of rifamycin, while accumulation of rifamycin B lowered 
the affinity of RifQ for its target sequences 368. This system is consistent with what is 
known for other TetR6family regulators that control natural product biosynthesis. 
 	
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10.6. GBLreceptors and antibiotic production in Actinobacteria other than 

	 
GBL6like molecules are produced by many actinobacteria, including the industrial 
important strains A. teichomyceticus (producer of teicoplanin), A. mediterranei (produces 
rifamycin), and Micromonospora echinospora (produces gentamicin) 369. The exact 
structures of the GBL molecules produced by these strains are unknown, but the type of 
GBL that is produced could be determined using binding assays with tritium6labeled GBL 
molecules as ligands 369, 370. These binding assays confirmed that A. teichomyceticus 
produces a GBL similar to virginiae butenolide (VB) derived from S. viginiae. The strains 
A. mediterranei and M. echinospora produce a GBL similar to IM62, derived from S. 	
lavendulae (see section 9.2) 369. In the rifamycin producer A. mediterranei, four genes that 

encode GBL6receptor paralogues are present, namely bamA1$bamA4 371. All four receptor 
proteins can bind GBLs derived from Streptomyces, including VB from S. virginiae and 
SCB1 from S. coelicolor. Only BamA1 was shown to bind the IM62 GBL , an autoregulator 
produced by A. mediterranei itself 369, 371.  
Kitasatospora setae, a member of a genus closely related to Streptomyces, 
harbours several GBL6receptors 264, 372. K. setae produces bafilomycins A1 and B1. These 
macrolides specifically inhibit vacuolar H+ 6ATPases and are used in studies of molecular 
transport in eukaryotes. The genome of K. setae contains three genes that are similar to 
GBL6receptors, namely ksbA, ksbB and ksbC 373. KsbA binds 3H6labeled SCB1, and 	
deletion of ksbA increases bafilomycin biosynthesis 372. Conversely, KsbC indirectly 

represses bafilomycin biosynthesis, perhaps via the activation of the gene for the 
autoregulator KsbS4 373. KsbC also indirectly activates the production of kitasetaline, a β6
carboline alkaloid, and of the kitasetaline derivative JBIR6133 373. 
Interestingly, Rhodococcus jostii, a genus of the Nocardiaceae produces the GBL 
(called RJB) that is structurally identical to a precursor of SCB2 (66dehydro SCB2) 
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produced by S. coelicolor, and can bind to the S. coelicolor GBL receptor ScbR 374. This 
suggests cross6family communication mediated by GBLs in the natural environment. The 
gene for GBL biosynthesis, gblA, is located in a GBL BGC that is conserved between 
different Rhodoccocus species. This GBL BGC also encodes a GBL6receptor protein 	
GblR and the biosynthesis enzyme GblE, which is an NAD6epimerase/dehydratase. 

Genome sequencing of R. jostii RHA1 indicated that the strain potentially has a rich NP 
biosynthetic repertoire. The precise role of GBLs in the regulation of natural product 
biosynthesis in Rhodococcus, and the value of the NPs these Actinobacteria can 
produce, merit further investigation.  
 
 
11. OUTLOOK 
Over the last decade it has become increasingly clear that Streptomyces species and 
other antibiotic6producing Actinobacteria produce only a small percentage of their 	
secondary metabolome under laboratory conditions. Accessing the chemistry specified by 

this ‘silent majority’ 6 also referred to as dark matter 6 without a doubt holds potential for 
drug discovery. This untapped resource can be harnessed by both genetic and non6
genetic methods which been reviewed recently 375. The proverbial ‘holy grail’ in this 
respect is development of small molecules that can simply be added to culture media to 
elicit the production of all or ideally only a subset of compounds. Progress has been 
achieved in this area (i.e. sugar6responsive antibiotic repressors, REEs, GBLs and 
manipulation of C, N and P concentrations, discussed above); the molecular insights that 
is reviewed above can be harnessed to develop strategies to activate antibiotic production. 
Clearly, more work is required with the identification of other small molecules. Reporter6	
based methods have therefore been developed to aid detection of activated or de6

repressed gene clusters 376, 377, and screening using small molecule libraries forms an 
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attractive black box alternative to rational approaches that are based on molecular insights 
378, 379. For details on molecular, environmental and HT screening approaches to find 
elicitors we refer the reader to recent reviews 35, 380. Elicitors are also instrumental in 
unsupervised metabolomics approaches, required to identify compounds in the complex 
metabolic matrix of microbial cultures 381. Here, significant fluctuation of the secondary 
metabolome needs to be achieved, allowing statistical correlation of a given bioactivity of 
interest to a specific metabolite and/or a BGC. NMR6 or MS6based metabolomics then 
facilitate the identification of the sought6after bioactive molecules 382, 383 384, 385. 	
Ultimately, the productivity of any given biosynthetic pathway is dictated by one or 

more CSRs. The examples provided by among others Salinispora show that BGCs may 	
be silent in one species of a given genus, and active in another. Thus, with the growing 	
wealth of genome sequence information, a promising strategy is to look for related 	
bacteria that harbour a close relative of the gene cluster of interest. Indeed, it is not 	
illogical to assume that over the hundreds of millions of years of evolution, the natural 	
products specified by the BGCs have remained structurally the same or highly similar, but 	
are expressed under different growth conditions or in response to different environmental 	
stimuli. The functionality of most putative CSRs can be deduced bioinformatically (i.e. as a 	
repressor or an activator). Therefore, an obvious strategy and one that is commonly 		
employed for elicitation of poorly expressed BGCs is augmentation of endogenous 	

regulatory system(s). For example, by deleting genes encoding repressors or over6

expressing those encoding activators 232, 386. This strategy depends upon the genetic 

tractability of the organism, but this is becoming less and less of a requirement as the 

cloning of large genomic fragments and their de novo synthesis becomes more feasible, 

which enables their tractability and heterologous expression in a panel of potential hosts 

3876389. Indeed, it is now possible to completely refactor the regulation of a biosynthetic 

pathway by replacing native promoters with those that are constitutively expressed to 

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increase production titres using CRISPR6Cas9 technology 390. Longer term, improved 

understanding of how secondary metabolism is controlled and the development of 
	
approaches to exploit this and/or efficient synthetic biology strategies to activate 


biosynthetic pathways are required in order to capitalise on the treasures beneath our feet. 
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 


Table 1. Major families of regulators involved in the control of antibiotic production. 

Representative examples and their host and target are indicated. 

 


∆
 	
  

 


SARP ActII6ORF4, 
RedD, CdaR 
S. coelicolor (+) Act, Red, Cda, respectively 	
AfsR S. coelicolor  (+) activates transcription of AfsS 	
FarR3/ Far4 S. lavendulae (+,6) Indigoidine, nucleoside and D6
cycloserine 




StrR (ParB
Spo0J) 
StrR S. griseus (+) streptomycin 

Tei15* Actinoplanes 
teichomyceticus 
(+) teicoplanin 
Dbv4 Nonomuraea sp. 
TCC39727 
(+) A40926 
LAL  
 
FscRI S. albus (+) candicidin and antimycin 
  AveR S. avermitilis (+,6) avermectin and oligomycin 

 Dbv3 Nonomuraea sp. 
ATCC39727 
(+) A40926 
TetR AtrA 
 
S. griseus  (+) Global regulator 

ArpA S. griseus  (6) GBL receptor, repressor of 
adpA  
	

ScbR S. coelicolor  (+,6) GBL receptor 

AraC/XylS AdpA S. griseus  activates StrR expression 

GntR DasR S. coelicolor (+,6) global regulator of antibiotic 
production; effector molecule is 
N6acetylglucosamine  




cAMP 
receptor 
protein  
Crp S. coelicolor  (+) regulator coordinating 
development, primary and 
secondary metabolism 


Orphan RR  RedZ S. coelicolor (+) Red 
GlnR S. coelicolor (+) Act and Red 
TCS AbsA1/AbsA2 S. coelicolor (6) Act, Red, Cda 
	
 AfsQ1/2 S. coelicolor (+) Act, Red, Cda; responds to 
nitrogen 


 PhoRP S. coelicolor  (+,6) Act; global regulator  

 DraR/K S. coelicolor (+,6) Act, Red, coelimycin, responds 
to high concentrations of 
nitrogen. 


 OsdR/K S. coelicolor (+) Act, responds to oxygen level 
ROK Rok7B7 S. coelicolor (+,6) Act, Red, Cda; CCR 

σ Factor  MibX/MibW  Microbispora 
corallina  
(+) microbisporicin 
 Sigma(AntA) S. albus  (+) antimycin.  



BldB  BldB S. coelicolor (+) antibiotic production, 
development and CCR 
 
. 
		


tRNA BldA Streptomyces 
species 
 leucine6tRNA for UAA codon. 
Translational control of 
antibiotic production and 



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morphogenesis 
XRE MmyB S. coelicolor (+) methylenomycin B; controlled 
by furans  
	


Wbl (WhiB
like protein) 
WblA S. coelicolor (6) pleiotropic regulator of 
antibiotic production and 
development  



LacI  AcrC Actinoplanes sp. 
SE50/110 
(6) acarbose 

LmbU  S. lincolnensis  (+,6) lincomycin  

	
Lrp/AsnC  SCO3361 S. coelicolor  (+) Act; control by amino acids  


NsdA NsdA S. coelicolor  (6) Act, Cda, Mmy 400 
IclR NdgR S. coelicolor 6  Act; dependent on amino 
acids. 


MarR DptR3 S. roseosporus + daptomycin 
 

* Streptomyces abbreviated with 'S.' 

# activation indicated by +, repression by 6. 

^ Act, actinorhodin; Cda, calcium6dependent antibiotic; Red, prodiginines; Mmy, 

methylenomycin. 

∆
 LAL, Large ATP6binding regulators of the LuxR family (in the text mentioned as LuxR);   
	
XRE, xenobiotic response element 


 

 

 

 

 

 

 

Table 2. Recently discovered transcriptional regulators that control antibiotic production in 

	. Orthologues also studied in S. avermitilis or S. venezuelae are indicated. 
	
 


Gene ID ^ Function(s) of the regulator(s) # Ref 
Regulators known to directly control antibiotic BGCs 
	 SCO3013/2 
SVEN2756/5 
TCS; MtrA activates actII6ORF4 and redZ and links 
their production to development. 
403 
	
 SCO3063/2; 
SAV3481/0 
TCS; regulator of actII$ORF4 and kasO in S. coelicolor 
and of olmRI in S. avermitilis. Impacts Red and Ave 
production in S. coelicolor and S. avermitilis, resp. 
113 
 SCO3361 Lrp/AsnC family positive regulator for Act production. 
Binds to actII6ORF4 (EMSA). 
399 
	 SCO3571 Regulator of primary and secondary metabolism; 
activates actII6ORF4, cdaR and cpkA (Chip6seq). 
103 
 SCO4159 
SAV4042 
Activator of actII6ORF4 and repressor of redZ in S. 
coelicolor (EMSA). Activator of aveR (avermectin) and 
repressor of olmRI/olmRII (oligomycin) in S. avermitilis 
(EMSA). 
152 

	 SCO4596 Atypical TCS with two kinase (C1 and C2); response 
regulator AbrC3 is a transcriptional activator of actII6
ORF4 (ChIP6chip); impacts Red production. 
101 
 SCO5803 Global regulator of the DNA damage response; 
Repressor of actII6ORF4 (EMSA). 
404 
 SCO6256 GntR family regulator of antibiotic production. Direct 
activator of cdaR and indirect repressor of Act 
production (EMSA). 
405 
 SCO6286 Activator of actII6ORF4, redD, redZ and cdaR, 143 
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repressor of cpkO and SCO6268 (cpk cluster) (Chip6
seq, EMSA). 
Regulators in pathway with missing link to antibiotic gene clusters 
 SCO1596 
SAV6741 
Orphan HK; plays global role in antibiotic biosynthesis, 
by influencing precursor supply, pleiotropic and 
pathway6specific antibiotic regulators. 
406 

	 SCO1744/5  TCS; represses Act, Red and Cda production and 
morphological differentiation. 
237 
 SCO2140 Lrp/AsnC family protein. Indirectly regulates ACT and 
CDA production or cooperate with other transcriptional 
regulators involved in production of these antibiotics 
(EMSA). 
407 

	 SCO2281 Orphan response regulator; upregulates Act, Red and 
Cda production and downregulates sigB, thus linking 
antibiotic production to osmotic stress response. 
408 
 SCO2964 LTTR; Negative regulator for Act and Red production 
trough upregulation of actII$ORF4 and redZ, 
respectively. Exact regulatory cascade remains 
unknown. 
409 
  SCO3892 ECF sigma factor; required for normal Act production 
under nitrogen limitation. 
358 
	
 SCO4126  ̶ 
SCO4131 
Operon for membrane proteins; affects differentiation 
and causes increased production of Act. 


! SCO4228 Activates Act and Red production. Exact regulatory 
cascade unknown. 
411 
 

^SCO, S. coelicolor; SAV, S. avermitilis; SVEN, S. venezuelae; See StrepDB for the full 

annotation (http://strepdb.streptomyces.org.uk). 

# Experimental evidence presented between brackets (EMSA, Electromobility shift assay; 

ChIP6Seq, chromosome immunoprecipitation combined with next6generation sequencing. 

 

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Figure 1. The PhoRP and AfsKRS systems and their interplay in regulation of 

nitrogen metabolism and antibiotic production. Black arrows indicate activation and 

red bars indicate repression, cyan arrows indicate expression of genes. During growth 
	
under phosphate deplete conditions, the global regulator PhoP is activated by the 


membrane6bound sensor kinase, PhoR. Activated PhoP acts directly upon BGCs by 

modulating expression of CSRs or other transcription factors, such as glnR, which controls 

expression of nitrogen metabolism genes and afsS, part of AfsKRS  regulatory system. 

PhoP may directly inhibit expression of nitrogen assimilation genes and has an indirect 

negative impact (through ScbAR system) on expression of afsK. KbpA and S6adenosyl6L6

methionine (SAM) can also modulate the activity of AfsK. The membrane associated 

kinase, AfsK, in turn, activates AfsR. AfsR interacts with the PhoP in several ways: it can 

directly repress expression of the phoRP regulon, compete for activation of afsS or as 

activator of glnR expression can upregulate expression of the genes responsible for 
	
nitrogen assimilation. 


 

Figure 2. CCR and the control of antibiotic production. Glucose repression is shown 

for primary and secondary metabolism. Black arrows indicate activation, red lines 

repression. Glucose kinase (Glk) is activated post6translationally in a glucose transport6

dependent manner (van Wezel et al., 2007). Glc, glucose; Fru, fructose, secondary sugars 

(energetically less favorable sugars, such as lactose, mannitol and glycerol). SI, substrate 

induction. Note that glucose is transported by an MFS transporter and not by the PTS in 

Streptomyces.  

 
	
Figure 3. The DasR regulatory network. The primary metabolism of S. coelicolor is 


shown for N6acetylglucosamine (GlcNAc), glucose (Glc) and glucosamine (GlcN). 
	
Glucosamine 66 phosphate (GlcN66P) is a central metabolite that stands at the crossroads 
	
of aminosugar metabolism, glycolysis, nitrogen metabolism and cell wall synthesis. GlcN6
	
6P and GlcNAc66P are ligands that modulate the DNA6binding activity of DasR. DasR is a 
	
global repressor of specialised metabolism. Internalised glucose is phosphorylated by 
	
glucose kinase (Glk), which is key to carbon catabolite repression in S. coelicolor. In turn, 
	
DasR suppresses CCR by downregulating Glk expression. The broken lines represent 
	
known routes that have not yet been fully characterised. 
	
 
		

	

Figure 4. Schematic illustration of a selection of genes corresponding to sites of 


AtrA binding in 	 Black and red solid black lines with arrow heads represent 


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previously described interactions associated with activation by AtrA and repression by 


DasR, respectively. The broken lines represent interactions identified by chromatin 


immunoprecipitation but not yet characterized AtrA binds to upstream regions of genes 


encoding CSRs (actII6ORF4, cdaR of S. coelicolorand salO of S. albus; the latter encodes 


the CSR for salinomycin biosynthesis). The activator AtrA and the repressor DasR 


compete for binding to the upstream regions of actII6ORF4 and cdaR and upstream 


regions of genes that are  involved in the uptake of GlcNAc (crr and nagE2). In addition 

	
AtrA binds to an upstream region of SCO0481, which encodes a protein that binds chitin, a 



rich source of GlcNac. The positive control of AtrA on GlcNac uptake suggest that AtrA 
increases Act production indirectly through enhanced GlcNAc6induced inactivation of 
DasR as well as directly through activation of actII6ORF4 transcription. AtrA also binds to 
upstream regions of genes involved in glycerol catabolism (gylR and glpk2 (SCO1658)).  
The binding of AtrA to the upstream region of genes involved in DNA replication (topA, 
DNA topoisomerase 1, uvrA, dnaQ)   cell division and sporulation  (ssgR and ftsK ) 
explains the role of AtrA in the control of morphological development.  
 
Figure 5. Initiation of development and antibiotic production. The developmental 	
programme starts with nutrient stress and growth cessation, followed by the accumulation 

of ppGpp. The autolytic dismantling of the cell wall (PCD) releases cell wall6derived 
metabolites that inhibit the activity of the nutrient sensory DasR. The onset of antibiotic 
production correlates temporally to the transition from vegetative to aerial growth, and is 
controlled by multiple pathway6specific and global regulators. Shown here are three key 
pleiotropic regulators, namely the antibiotic repressor DasR which responds to 
phosphorylated aminosugars likely derived from PCD, the activator AtrA (signal unknown) 
and AdpA, which responds to the accumulation of A6factor (synthesized by AfsA). Bld 
proteins and environmental signals control the procession towards aerial growth and 
antibiotic production. Whi proteins control aerial growth. Eventually, FtsZ accumulates and 	
localizes to septum sites in an SsgAB6dependent manner. Solid black arrows represent 

major transitions in development. The arrow indicates the FtsZ accumulation checkpoint 
controlled by the Whi proteins. Red lines indicate repression. 
 
Figure 6. Regulation of glycopeptide biosynthetic gene clusters. Shown are the 
BGCs for teicoplanin (tei), balhimycin (bal) and A40926 (dbv). Known and putative binding 
sites for StrR (purple) are indicated in the clusters with closed and open circles, 
respectively. The consensus sequence for the StrR binding sites GTCCAR(N)17TTGGAC 
Page 73 of 81 Natural Product Reports
74 
 
is shared between all three BGCs. Genes regulated by LuxR (magenta) are indicated with 
an asterisk. Experimentally confirmed operons are indicated with an arrow. The primary 	
CSR of the teicoplanin BGC is Tei15*, which positively regulates the expression of LuxR6

family regulator Tei16* and of the SARP6family regulator Tei31*, with both regulators 
having unknown targets. The bal cluster is regulated by the CSR BbR, and lacks a gene 
for a LuxR regulator. The primary CSR of the dbv cluster is the LuxR regulator Dbv3, 
which positively regulates the expression of StrR regulator Dbv4, most likely indirectly. For 
details see the text. BGCs adapted from the MiBIG database 412. 
 
Figure 7. The regulation of microbisporicin production by "		
 	

. 
Nutritional stress leads to the RelA6dependent production of ppGpp which results in the 
expression of the LuxR6family regulator MibR. MibR activates the expression of 	
mibABCDTUV, which results in the production of an immature and less active form of 

microbisporicin (grey circle) and the means for its export. A basal level of expression of the 
genes encoding an ECF σ6factor (MibX) / anti6σ6factor (MibW) system enables a feed6
forward regulatory mechanism. The immature compound itself or possibly interaction with 
its lipid II to be sensed by MibW, at which point the ECF σ6factor, MibX is released. MibX 
then in turn activates its own expression and that of mibR as well as the remaining genes 
in the BGC. 
 
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